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A B S T R A C T
Background
It has been proposed that antioxidants may prevent cellular damage in the retina by reacting with free radicals that are produced in the
process of light absorption. Higher dietary levels of antioxidant vitamins and minerals may reduce the risk of progression of age-related
macular degeneration (AMD).
Objectives
The objective of this review was to assess the effects of antioxidant vitamin or mineral supplementation on the progression of AMD in
people with AMD.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2012, Issue 8),
Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE
(January 1946 to August 2012), EMBASE (January 1980 to August 2012), Allied and Complementary Medicine Database (AMED)
(January 1985 toAugust 2012),OpenGrey (System for InformationonGrey Literature inEurope) (www.opengrey.eu/), themetaRegister
of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International
Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the
electronic searches for trials. We last searched the electronic databases on 20 August 2012. We searched the reference lists of identified
reports and the Science Citation Index. We contacted investigators and experts in the field for details of unpublished studies. We also
searched for systematic reviews of harms of vitamin supplements.
Selection criteria
We included randomised trials comparing antioxidant vitamin or mineral supplementation (alone or in combination) to placebo or no
intervention in people with AMD.
Data collection and analysis
Two authors assessed risk of bias and extracted data from the included trials. Where appropriate, we pooled data using a random-effects
model unless three or fewer trials were available in which case we used a fixed-effect model.
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Main results
Thirteen trials (6150 participants) were included in this review. Over half the participants (3640) were randomised in one trial (AREDS
in the USA), which found a beneficial effect of antioxidant (beta-carotene, vitamin C and vitamin E) and zinc supplementation on
progression to advanced AMD (adjusted odds ratio (OR) 0.68, 95% confidence interval (CI) 0.53 to 0.87) over an average of 6.3 years.
People taking supplements were less likely to lose 15 or more letters of visual acuity (adjusted OR 0.77, 95%CI 0.62 to 0.96). The other
trials, in general, had shorter follow-up (less than two years). No evidence for an effect of supplementation was seen in these smaller
trials of shorter duration. Overall we considered the strength of the evidence to be moderate. We did not consider included trials, in
general, to be at risk of bias, although we found it difficult to assess reporting biases. The main reason for downgrading the strength of
the evidence was because, for several analyses, only one trial was included and therefore consistency of the findings could not be assessed.
The included trials reported the following adverse effects: hospitalisation for genito-urinary problems was more common in people
taking zinc and yellowing of skin was more common in people taking antioxidants. Systematic searching of the literature identified other
potential harms of vitamin supplementation, in particular an increased risk of lung cancer in smokers associated with beta-carotene
supplements, but we were unable to identify a good systematic review of the evidence for harms of nutritional supplementation.
Authors’ conclusions
People with AMD may experience delay in progression of the disease with antioxidant vitamin and mineral supplementation. This
finding is drawn from one large trial conducted in a relatively well-nourished American population. The generalisability of these findings
to other populations is not known. Although generally regarded as safe, vitamin supplements may have harmful effects. A systematic
review of the evidence on harms of vitamin supplements is needed.
P L A I N L A N G U A G E S U M M A R Y
Antioxidant vitamins and mineral supplements to slow down the progression of age-related macular degeneration
Age-related macular degeneration (AMD) is a condition affecting the central area of the retina (back of the eye). The retina can
deteriorate with age and some people get lesions that can lead to loss of central vision. It has been suggested that progression of the
disease may be slowed down in people who eat a diet rich in antioxidant vitamins (carotenoids, vitamins C and E) or minerals (selenium
and zinc). We identified 13 randomised controlled trials that included 6150 participants; five trials based in the USA, two in the UK,
two trials in Austria, and one trial in each of a further four countries (Australia, China, Italy and Switzerland). The review of trials found
that supplementation with antioxidants and zinc may be of modest benefit in people with AMD. This was mainly seen in one large
trial that followed up participants for an average of six years. The other smaller trials with shorter follow-up do not provide evidence of
any benefit. Large well-conducted trials in a range of populations and with different nutritional status are required. Although generally
regarded as safe, vitamin supplements may have harmful effects. A systematic review of the evidence on harms of vitamin supplements
is needed.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Multivitamin antioxidant vitamin or mineral supplement for age-related macular degeneration
Patient or population: patients with age-related macular degeneration
Settings: community
Intervention: multivitamin antioxidant vitamin or mineral supplement
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Multivitamin antioxidant
vitamin or mineral sup-
plement
Distance visual acuity
(loss of 3 or more lines)
LogMAR
Follow-up: mean 6.3
years
Moderate OR 0.77
(0.62 to 0.96)
3640
(1 study)
⊕⊕⊕©
moderate1
300 per 1000 248 per 1000
(210 to 291)
Progression to advanced
AMD
Grading of fundus pho-
tographs
Follow-up: mean 6.3
years
Moderate OR 0.68
(0.53 to 0.87)
3640
(1 study)
⊕⊕⊕©
moderate1
300 per 1000 226 per 1000
(185 to 272)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
AMD: age-related macular degeneration; CI: confidence interval; OR: odds ratio; SMD: standardised mean difference
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded for inconsistency: only one study so not possible to assess consistency of findings.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Age-relatedmacular degeneration (AMD) is a disease affecting the
central area of the retina (macula). In the early stages of the disease
lipid material accumulates in deposits underneath the retinal pig-
ment epithelium. These deposits are known as drusen and can be
seen as pale yellow spots on the retina. The pigment of the retinal
pigment epitheliummay become disturbedwith areas of hyperpig-
mentation and hypopigmentation. In the later stages of the disease
the retinal pigment epithelium may atrophy completely. This loss
can occur in small focal areas or can be widespread (geographic).
In some cases new blood vessels grow under the retinal pigment
epithelium and occasionally into the subretinal space (exudative or
neovascular AMD). Haemorrhage can occur which often results
in increased scarring of the retina.
The early stages of the disease are in general asymptomatic. In
the later stages there may be considerable distortion of vision and
complete loss of visual function, particularly in the central area of
vision. Population-based studies suggest that in older people (80
years and above) approximately one in three people have early signs
of the disease (Klein 1992) and one in eight people have late-stage
disease (Owen 2012)). It is the most common cause of blindness
and visual impairment in industrialised countries (Bunce 2010).
Description of the intervention
Photoreceptors in the retina are subject to oxidative stress through-
out life due to combined exposures to light and oxygen. It has
been proposed that antioxidants may prevent cellular damage in
the retina by reacting with free radicals produced in the process
of light absorption (Christen 1996). Antioxidants are any vitamin
or mineral which is known to have antioxidant properties in vivo
or which has been shown to be an important component of an
antioxidant enzyme present in the retina. The following vitamins
and minerals are usually considered to be ’antioxidant’: vitamin
C, vitamin E, carotenoids, selenium and zinc.
There are a number of non-experimental studies that have exam-
ined the possible association between antioxidant micronutrients
and AMD, although few studies have examined supplementation
specifically. Data on vitamin intake in observational studies should
be considered cautiously as people who have a diet rich in antiox-
idant vitamins and minerals or who choose to take supplements
regularly, are different in many ways from those who do not; these
differencesmay not be adequately controlled by statistical analysis.
The results of these observational studies have been inconclusive.
How the intervention might work
Photoreceptors in the retina are subject to oxidative stress through-
out life due to combined exposures to light and oxygen. It has
been proposed that antioxidants may prevent cellular damage in
the retina by limiting the damaging effects of free radicals pro-
duced in the process of light absorption (for a review see Christen
1996). Antioxidant vitamin and mineral supplements are increas-
ingly being marketed for use in age-related eye disease, including
AMD.
Why it is important to do this review
People with AMD need to have reliable information in order to
decide whether or not to take vitamin supplements.
O B J E C T I V E S
The objective of this review was to assess the effects of antioxidant
vitamin or mineral supplementation, alone or in combination, on
the progression of AMD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
This review included randomised controlled trials.
Types of participants
Participants in the trials were people with AMD in one or both
eyes.
Types of interventions
We included trials in which antioxidant vitamin or mineral sup-
plementation, alone or in combination, was compared to placebo
or no intervention. Antioxidants were defined as any vitamin or
mineral which is known to have antioxidant properties in vivo or
which is known to be an important component of an antioxidant
enzyme present in the retina. The following were considered: vi-
tamin C, vitamin E, carotenoids (including the macular pigment
carotenoids lutein and zeaxanthin), selenium and zinc.
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Types of outcome measures
Primary outcomes
The primary outcome for this review was visual acuity.
As one of the consequences of AMD is a progressive loss of vision,
our primary outcome was loss of 3 or more lines of visual acuity
which, if measured on a logMAR chart, reflects a doubling of the
visual angle. This is a meaningful clinical change for patients. We
also report visual acuity as a continuous measure as this was often
reported by the included trials, however, this was not defined a
priori.
Secondary outcomes
Secondary outcomes included progression of the disease as defined
by study investigators. This was usually reported as a dichotomous
outcome.
We also planned to assess quality of life and adverse effects, if data
were available.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) 2012, Issue 8, part of The Cochrane Library.
www.thecochranelibrary.com (accessed 20 August 2012), Ovid
MEDLINE, Ovid MEDLINE In-Process and Other Non-In-
dexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE
(January 1946 to August 2012), EMBASE (January 1980 to
August 2012), Allied and Complementary Medicine Database
(AMED) (January 1985 to August 2012), OpenGrey (System for
Information on Grey Literature in Europe) (www.opengrey.eu/),
the metaRegister of Controlled Trials (mRCT) (www.controlled-
trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the
WHO International Clinical Trials Registry Platform (ICTRP) (
www.who.int/ictrp/search/en). We did not use any date or lan-
guage restrictions in the electronic searches for trials. We last
searched the electronic databases on 20 August 2012.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1), MEDLINE (Appendix 2), EMBASE (Appendix
3), AMED (Appendix 4), OpenGrey (Appendix 5), mRCT
(Appendix 6), ClinicalTrials.gov (Appendix 7) and the ICTRP
(Appendix 8).
For the update in 2012 we specifically looked for adverse effects
using a simple search aimed to identify systematic reviews of ad-
verse effects of vitamin supplements, see Appendix (Appendix 9)
for search strategy.
Searching other resources
We searched the reference lists of identified trial reports to find
additional trials. We used the Science Citation Index to find stud-
ies that cite the identified trials. We contacted investigators of in-
cluded studies to identify additional published and unpublished
studies.
Data collection and analysis
Selection of studies
Both authors assessed the titles and abstracts of all reports of trials
identified by the electronic searching. We obtained the full texts
of possibly relevant trials. We selected relevant studies according
to the definitions in the ’Criteria for considering studies for this
review’.
Data extraction and management
The overall objective of the review was to assess the impact of
antioxidant vitamin and mineral supplements on the progression
of AMD. Trials in this area fall into two broad categories: those
evaluating a single vitamin or mineral (for example, vitamin E or
zinc) and those investigating a broad-spectrum formulation (for
example, Ocuguard). The following comparisons were considered
in this review.
1. Broad-spectrum formulation versus placebo. Within this
category fall all the broad-spectrum formulations which include
two or more antioxidant vitamins or minerals.
2. Single-component formulations versus placebo. Currently
only vitamin E, zinc and lutein have been studied as single
formulations, however, it is likely that in future other trials will
be published which investigate individual components.
3. All trials of broad-spectrum or single component studies
together.
We extracted data using a standardised form developed by the
Cochrane Eyes and Vision Group. For the initial review we sent
these data for verification to the trial investigators of all studies
included in the review. In the update (2012) data were extracted
by both authors, compared, disagreements resolved by discussion,
and data cut and pasted into Revman by one author and checked
by the other.
Assessment of risk of bias in included studies
We assessed risk of bias using The Cochrane Collaboration’s tool
for assessing the risk of bias as described in Chapter 8 of the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011).
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Measures of treatment effect
In general the risk ratio is to be preferred when the proportion
of the control group experiencing the event of interest is greater
than 10%. However, in this particular case the main trial (from
which over most of the information on this topic is available) re-
ported odds ratios (OR) and their confidence intervals only (de-
rived from repeated measures logistic regression) and therefore we
used the OR as the main measure of effect. We entered the data
into Revman using the generic inverse variance method. We cal-
culated the standard error from the confidence interval from each
study. In discussion of the results of the review, where possible,
we converted the pooled OR back to the risk ratio (RR) using the
following formula: RR = OR/1-ACR*(1-OR) where ACR is the
assumed risk in the control group as given in Chapter 12.5.4.4.
of the Cochrane Handbook for Systematic Reviews of Interventions
(Schünemann 2011).
For continuous outcomes we used the standardised mean differ-
ence (SMD) as outcomes were measured on different scales. For
visual acuity outcomes, we corrected for differences in direction
between Snellen and logMAR scales by multiplying the Snellen
decimal values by -1. Where possible, we checked for skewness
using methods outlined in Chapter 9.4.5.3 of theCochrane Hand-
book for Systematic Reviews of Interventions (Deeks 2011).
Unit of analysis issues
The main study design method in this area is the parallel-group
randomised controlled trial. Cluster-randomised trials are unlikely
but would still be considered. Cross-over studies would not be
appropriate in this area because of the uncertain and complex
natural history of AMD. Currently no such studies have been
identified, but if they are in the future, we will only use data from
the first phase.
Some studies report findings on right eyes and left eyes separately.
As there is no hypothesis that the effect of antioxidant supplements
should differ according to eye, we only included data for right eyes
in the analyses.
Dealing with missing data
The data included in the review represent an ’available case analy-
sis’. The majority of the data in the current review come from one
large trial which had a follow-up of nearly 98%.
Currently one study (Stur 1996) specifically excluded people who
experienced a neovascular event (one component of late-stage
AMD) from the analyses. The published report did not give
enough information to include these people in the analyses.
Assessment of heterogeneity
We assessed heterogeneity by looking at the forest plots to see
whether the effect measures for the different studies were in the
same direction and of a similar order of effect. An I2 statistic value
of 50% or more was taken to indicate considerable inconsistency
of results such that a pooled result may be inaccurate and should
not be reported.
The main clinical heterogeneity is the type of supplement. This is
incorporated into the analysis strategy by considering the formu-
lations by type.
Assessment of reporting biases
In future versions of this review, when sufficient trials are included
in the meta-analyses (10 or more), we plan to examine the funnel
plot to assess whether there is any evidence that smaller studies are
reporting larger effects, which may indicate publication bias.
We completed an outcome reporting matrix for the current review
(following the methods of Kirkham 2010) to assess the potential
for selective outcome reporting bias.
Data synthesis
We pooled data using a random-effects model because it is likely
that the effects of antioxidant vitamin and mineral supplementa-
tion may vary in different population groups (for example, by age,
sex, stage of disease, nutritional status etc). When there were three
or fewer trials we used a fixed-effect model.
Subgroup analysis and investigation of heterogeneity
Currently there are not enough studies to performuseful subgroup
analyses and these are not proposed for this version of the review.
One characteristic that may be important is the type of AMD or
severity of AMD. Subgroup analyses on type or severity of AMD
may be considered in future.
Sensitivity analysis
A sensitivity analysis was not planned.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Results of the search
See Appendix 11 for details of searches run previously for this
review.
An update search was done in August 2012 which yielded 640
records. The Trials Search Co-ordinator scanned the search results
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and removed335 referenceswhichwere not relevant to the scope of
the review.We screened the title and abstracts of the remaining 305
references. We rejected 277 references as not eligible for inclusion
in the review. We assessed the hard copies of 28 reports of 27
studies and categorised them as follows:
• We included four new trials (Bartlett 2007; CARMIS;
LISA; Newsome 2008: see ’Characteristics of included studies’).
• We excluded 14 studies (Connolly 2011;
ISRCTN35481392; ISRCTN57556290; ISRCTN81595685;
Landrum 2012; NCT00121589; NCT00006202;
NCT00718653; NCT00563979; NCT00564902; Nolan 2012;
PHS II; Sasamoto 2011; Vidal 2011: see ’Characteristics of
excluded studies’).
• We identified three studies that have been completed but
not yet published (CARMA; Falsini 2010; NCT00800995: see
’Characteristics of studies awaiting classification’). We will assess
these studies when data become available.
• One study is awaiting assessment because it requires
translating (Dawczynski 2012).
• We identified four ongoing studies (AREDS2;
NCT00879671; NCT00893724; NCT01048476: see
’Characteristics of ongoing studies’).
• One study was not eligible but described possible adverse
effects (Eller 2012).
Included studies
Below is a summary of the 13 trials included in this review. See
’Characteristics of included studies’ for detailed information on
individual trials.
Types of participants
The average age of people participating in the trials was 72 years
(median from included trials that reported age). On average,
slightly more women thanmenwere recruited (median percentage
female 56%) with the exception of AMDSG and Veterans LAST
study where predominantly men were enrolled. In AREDS it was
noted that people taking part in the trial were relatively well-nour-
ished compared to the general population.
People taking part in the trials were identified by referral from
local ophthalmologists (Kaiser 1995; Newsome 1988), from peo-
ple attending Department of VeteransMedical Centers (AMDSG;
Veterans LAST study), from retinal specialty clinics and gen-
eral population volunteers (AREDS), from an eye outpatient
clinic (Stur 1996; Wang 2004) and from the general population
(VECAT). Bartlett 2007 recruited by sending letters to “local op-
tometrists, ophthalmologists and a specialist centre for rehabilitation
of people with sight loss” and then patients were seen at the Univer-
sity research centre. In CARMIS, Holz 1993, LISA and Newsome
2008 it was not clear how participants were identified.
The trials enrolled groups of people with AMD at different stages
of the disease: AMDSG, CARMIS, Bartlett 2007, Holz 1993;
Newsome 2008 and Veterans LAST study considered people with
early macular degeneration only; Newsome 1988 and Wang 2004
examined people with both early and late-stage disease; Stur 1996
enrolled only people with late-stage disease in one eye;Kaiser 1995
recruited people with “non-serous” AMD. In AREDS participants
had a range of disease frommild or borderline features to advanced
AMD, which was defined as geographic atrophy involving the
centre of the macula or features of choroidal neovascularisation.
The majority of the participants in VECAT had no or mild age-
related maculopathy. LISA recruited individuals in categories 2, 3
and 4 according to AREDS criteria (similar to the participants in
AREDS).
Types of intervention
Three trials compared zinc sulfate 200 mg daily versus placebo
(Holz 1993; Newsome 1988; Stur 1996). Two trials compared a
broad-spectrum antioxidant complex versus placebo (AMDSG -
Ocuguard; Kaiser 1995 - Visaline). VECAT compared vitamin E
(500 international units (IU) daily) with placebo. In AREDS a 2
x 2 factorial design was used. Participants were randomised into
four groups: placebo, zinc alone (80 mg daily), antioxidants (vita-
min C 500 mg, vitamin E 400 IU and beta-carotene 15 mg) alone
and zinc plus antioxidants. In AREDS 67% of participants took
other multivitamin supplements to recommended daily allowance
levels (Centrum). The Veterans LAST study compared lutein 10
mg daily to lutein plus a broad-spectrum antioxidant (OcuPower).
Bartlett 2007 compared an antioxidant formulation containing
lutein 6 mg, retinol 750 µg, vitamin C 250 mg, vitamin E 34 mg,
zinc 10 mg and copper 0.5 mg to placebo. CARMIS compared a
similar formulation (vitamin C (180 mg), vitamin E (30 mg), zinc
(22.5 mg), copper (1 mg), lutein (10 mg), zeaxanthin (1 mg) and
astaxanthin (4 mg)) to no intervention. Newsome 2008 investi-
gated 25 mg of zinc-monocysteine supplement. The Chinese trial
studied zinc oxide (80 mg daily), vitamin C (dose unknown) and
vitamin E (dose unknown) (Wang 2004). LISA compared lutein
(Lutamax, 20 mg once daily for three months followed by 10 mg
once daily for three months) versus placebo, The duration of sup-
plementation in these trials ranged from six months to seven years.
Types of outcome measures
The trials used a variety of different ways of measuring and re-
porting outcomes. AMDSG and Veterans LAST study measured
visual acuity using a Snellen chart and converted the score into log-
MAR units. AREDS, CARMIS, Bartlett 2007, LISA, Newsome
1988 and Newsome 2008 used the visual acuity chart devel-
oped as part of the Early Treatment of Diabetic Retinopathy
Study (ETDRS 1980). Stur 1996 and VECAT used Bailey-Lovie
Charts #4 and #5 (National Vision Research Institute, Australia).
Some studies reported visual acuity as a continuous outcome
(AMDSG;CARMIS; Bartlett 2007; Kaiser 1995;Newsome 2008;
Stur 1996), others used a cut-off of loss of 10 (Newsome 1988) or
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15 letters of acuity (AREDS). A loss of 15 letters of acuity on the
EDTRS chart is equivalent to a loss of 3 lines of vision read on
the chart and is the same as experiencing a doubling of the visual
angle.
In most studies disease progression was assessed by grading stereo-
scopic colour photographs of the retina. Stur 1996 used the Wis-
consin Age-Related Maculopathy Grading System (Klein 1991);
AMDSG used the grading system developed as part of the Chesa-
peake Bay Waterman Study (Bressler 1989); VECAT used the
International Grading System (ARMSG 1995); AREDS adapted
the Wisconsin system and this adapted system was also used by
Bartlett 2007 and LISA. The Wisconsin, AREDS and Interna-
tional Systems are closely related, but the AREDS grading system
is the most widely adopted at present. All these grading systems
involve classification into categories according to the number and
type of drusen, pigmentary abnormalities and presence of geo-
graphic atrophy or neovascularisation. In AMDSG and Bartlett
2007 these categories were accorded a score which was analysed
as a continuous measure. Newsome 1988 recorded the number
of cases of increased drusen, pigment abnormalities and atrophy.
Kaiser 1995 and Newsome 2008 did not include any measures of
progression of AMD. CARMIS included a fundus examination at
follow-up examinations but did not report progression of AMD.
AREDS reported data for three categories of participant: (i)mild or
borderline AMD features (n = 1063); (ii) AMD but not advanced
AMD (n = 1621) and (iii) advanced AMDor reduced visual acuity
due to AMD in one eye (n = 956). Advanced AMD was defined
as signs of geographic atrophy involving the centre of the macula
or signs of choroidal neovascularisation (defined as the presence
of fluid, blood or fibrovascular tissue under the retina or retinal
pigment epithelium).
The study followed up 90% of the cohort by the end of five years;
the mean follow-up time was 6.3 years. On the basis of having
missed the last two consecutive study visits, 2.4% were defined as
lost to follow-up. In the borderline AMD group, 1.3% progressed
to advanced AMDby five years (15 AMD events); in the advanced
AMD category, 43% progressed to advanced AMD (in the other
eye) by five years and 18% progressed in the intermediate group.
At five-year follow-up 71% of participants were taking 75% or
more of their tablets.
The investigators found that individuals with outcomes such as
signs of advanced AMD and visual acuity loss of 15 or more letters
could recover later on. Approximately 8% of the identified cases
of advanced AMD, based on central grading of colour stereo pho-
tographs, apparently recovered as the AMD lesions were not seen
on subsequent yearly photographs. The report did not distinguish
between grading errors and verified disappearance of lesions. For
this reason they used repeated measures logistic regression which
counts each event but also allows for the fact that the event could
’recover’.
Outcomes were not clearly defined for the Chinese trial (Wang
2004).
Excluded studies
Details of excluded studies are provided in ’Characteristics of
excluded studies’.
Risk of bias in included studies
Figure 1 and Figure 2 summarise the ’Risk of bias’ assessment.
Overall we considered the trials to be generally at low risk of bias
for themain types of bias, in particular selection bias (allocation se-
quence generation and concealment) and performance and detec-
tion bias. This is because all trials (with the exception of CARMIS)
had a placebo control. Two trials were not well reported (Holz
1993; Wang 2004).
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Figure 1. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Inmost trials randomisation appeared to have been executed prop-
erly, that is, an unpredictable sequence of treatment allocation was
concealed adequately from people recruiting participants into the
trial. As Holz 1993 has only been published in abstract form to
date the details of randomisation were not clear. In AMDSGmore
people in the placebo group withdrew (six) compared to the treat-
ment group (one).
Blinding
In AREDS four people were documented as being unmasked to
study group. More people in the antioxidant group (8.3%) re-
ported changes in skin colour (yellowing) than in the placebo
group (6.0%, P < 0.01) and more people in the zinc groups
reported difficulty swallowing the study tablets (17.8% versus
15.3%, P = 0.04). However, there was little evidence of unmask-
ing when at the end of the study participants were asked to guess
their treatment assignment. The percentages of participants who
guessed correctly, by treatment assignment, were: placebo 17%,
antioxidants alone 16%, zinc alone 18% and antioxidants plus
zinc 16%.
In the Veterans LAST study the tablets were apparently identical
in appearance but it was not clear whether taste or systemic effects
differed between the different groups.
Incomplete outcome data
Information on attrition bias was not so clearly reported and it
was difficult to assess how likely this bias was.
In Stur 1996 analysis of the main outcome measures (visual func-
tion and progression of disease) was not done on a strictly in-
tention-to-treat basis as anyone experiencing the study endpoint
of late-stage AMD (neovascularisation) was withdrawn from the
study. Contact with the trial investigator revealed that all of these
participants ended up with visual acuity of 20/200 or less and that
these participants were excluded because the investigators wished
to detect functional changes caused by degeneration of the retinal
pigment epithelium and the sensory retina and not vision losses
caused by choroidal neovascularisation.
Selective reporting
See the outcome reporting matrix (Table 1). In general there was
little evidence of selective outcome reporting. The exception was
for visual acuity. In two studies, visual acuity datawere not reported
but it was stated that there were no significant differences between
groups (Holz 1993; VECAT) and in one further study visual acuity
wasmeasured and not reported andwe judged it likely that this was
because no statistically significant differences were found (Wang
2004).
Effects of interventions
See: Summary of findings for the main comparison
Multivitamin antioxidant vitamin or mineral supplement for
age-related macular degeneration; Summary of findings 2 Zinc
for age-related macular degeneration; Summary of findings 3
Vitamin E for age-related macular degeneration; Summary of
findings 4 Lutein for age-related macular degeneration
Table 2 provides more information on the outcomes and follow-
up times relating to the data included in these analyses.
Multivitamin supplement versus placebo
These analyses were restricted to trials of multivitamin and min-
eral supplements: AREDS (vitamins C, E, beta-carotene and
zinc), AMDSG (Ocuguard), Bartlett 2007 (lutein, retinol, vita-
min C, E, zinc), CARMIS (lutein, zeaxanthin, astaxanthin, vi-
tamin C, E, zinc), Kaiser 1995 (Visaline) and Veterans LAST
study (Ocupower). See ’Characteristics of included studies’ for
details of vitamins and minerals included in Ocuguard, Visaline
and Ocupower. Currently data for CARMIS are not available in a
form suitable for inclusion in the analyses in this review but have
been requested from the study investigators; the trial publication
reported stabilisation of visual acuity in the treated group com-
pared to the non-treated group.
Distance visual acuity: loss of 3 or more lines
Only AREDS reported visual acuity data in a dichotomous format.
People who received antioxidant vitamins plus zinc were less likely
to lose 15 or more letters of visual acuity. The odds ratio (OR)
adjusted for age, sex, race, AMD category and baseline smoking
status was 0.77 (95% confidence interval (CI) 0.62 to 0.96).
Distance visual acuity: mean
Trials reporting visual acuity in continuous format were smaller
and had shorter treatment and follow-up durations (six months to
18months) (AMDSG; Bartlett 2007, Kaiser 1995; Veterans LAST
study). A total of 89 people were randomised to treatment and 72
to placebo in pooled analyses of all four trials. The results of these
trials were consistent I² = 0%. Little effect of treatment on visual
acuity was seen from these analyses. The pooled standardisedmean
difference (SMD) was 0.17 (95%CI -0.14 to 0.49) (Analysis 1.1).
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Progression of AMD: dichotomous
Only the AREDS trial contributed to this outcome. People taking
antioxidant vitamins plus zinc were less likely to progress to ad-
vanced AMD. The OR adjusted for age, sex, race, AMD category
and baseline smoking status was 0.68 (95% CI 0.53 to 0.87).
Progression of AMD: continuous
Two trials reported the progression of AMD in a continuous for-
mat (AMDSG; Bartlett 2007), with 48 people randomised to
treatment and 32 to control. There was little evidence of any effect
of treatment (Analysis 1.2).
Zinc and zinc-monocysteine versus placebo
Four trials have investigated the effect of zinc supplementation
(AREDS; Holz 1993 (published in abstract form only); Newsome
1988; Stur 1996). In addition we are aware of one unpublished
study for which we have no data (France 1998). One trial has
investigated zinc-monocysteine (Newsome 2008).
Distance visual acuity: loss of 3 or more lines
Two trials reported visual acuity data in this format (AREDS;
Newsome 1988). The pooled analyses include a total of 977 people
randomised to zinc supplementation and965 toplacebo.The trials
were consistent I2 = 0%. There was a beneficial effect of treatment
on visual acuity (pooled OR 0.81, 95% CI 0.66 to 0.99) (Analysis
2.1).
Distance visual acuity: mean
Two trials provided data for this outcome (Newsome 1988; Stur
1996). A total of 77 people were randomised to zinc supplemen-
tation and 78 to placebo in these two trials which had a maxi-
mum treatment and follow-up duration of 24 months. The re-
sults of these trials were less consistent, I2 = 56.6% (Analysis 2.2).
Newsome 1988 found that there was more visual acuity loss in
the control group than the treatment group although this did not
reach statistical significance. Stur 1996 found little difference be-
tween the two groups with respect to mean visual acuity at the end
of the study.
In Stur 1996 the primary outcome was incidence of choroidal
neovascularisation (CNV) in all patients. During the treatment
period, a CNV developed in the study eye in 14 patients (nine
in the treatment group, five in the placebo group). People who
experienced a CNV were not included in the analyses of visual
acuity.
Progression of AMD: dichotomous
Three trials provided data for this outcome (AREDS; Holz 1993;
Stur 1996). A total of 969 people were randomised to zinc sup-
plementation and 974 to placebo. Overall, there was an observed
benefit of treatment (Analysis 2.3). The pooledORwas 0.73 (95%
CI 0.58 to 0.93). Stur 1996 had quite different results to the other
two trials. Over the treatment period, nine people experienced a
CNV in the study eye in the zinc group compared to five people in
the placebo group. This may have been a chance finding, however.
The OR for that trial (2.31) had wide confidence intervals and
the results are therefore also consistent with a protective effect of
treatment (95%CI 0.58 to 9.26). Overall, the I2 value was 29.0%.
Holz 1993 has been published in abstract form only so we have
little information about this trial.
Only one trial has investigated zinc-monocysteine to date (
Newsome 2008). At six months, people taking zinc-monocysteine
read more letters (distance visual acuity). In people treated with
zinc-moncysteine, the mean (SD) number of letters read correctly
on an EDTRS charts with best correction was 39.027 (0.672) at
baseline and 43.432 (0.784) at six months in their right eyes. In
people taking placebo the values were 40.297 (0.649) at baseline
and 39.243 (0.921) in their right eyes. Differences between the
groups were statistically significant. Similar findings were seen for
the left eye.
Vitamin E versus placebo
There has only been one trial investigating vitamin E alone (VE-
CAT). This trial randomised 587 participants to vitamin E sup-
plementation and 592 to placebo and followed them up for four
years on average. Over 80% of participants in this trial did not
have signs of AMD.
There was no evidence of any effect of treatment on visual acuity;
59 people in the vitamin E group and 57 people in the placebo
group lost more than nine letters of acuity (equivalent to 2 or more
lines) on the Bailey-Lovie chart (OR 1.05, 95% CI 0.71 to 1.54).
Similarly there was no evidence of effect on the progression of
AMD; on grading of photographs 95 of 491 people in the vitamin
E group showed progression compared with 90 of 506 people in
the placebo group (OR 1.11, 95% CI 0.81 to 1.53). The results of
clinical grading were that 40 of 508 people in the vitamin E group
and 31 of 514 people in the placebo group showed progression
(OR 1.33, 0.82 to 2.16).
Lutein or zeaxanthin versus placebo
Distance visual acuity: mean
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There have been two trials published to date comparing supple-
mentation with lutein versus placebo and reporting outcomes of
relevance to this review (LISA; Veterans LAST study).
Veterans LAST study was small with a total of 25 people ran-
domised to lutein supplementation and 27 to placebo; the treat-
ment duration and follow-up was 12 months. The only outcome
of relevance to this review, for which data could be extracted, was
mean visual acuity at the end of the study. This showed little evi-
dence of any effect of treatment: MD logMAR acuity 0.04 (95%
CI -0.15 to 0.23). The power of the study was low.
LISA was larger with 84 participants in the lutein group and 42
participants receiving placebo. They reported a non-significant
improvement in visual acuity in the lutein group over six months
however currently data are not available in a form suitable for
inclusion in this review; we have requested the data from the study
authors.
Any multivitamin or single component antioxidant
supplement versus placebo
Distance visual acuity: loss of 3 or more lines (15 or more
letters)
Three trials contributed to this analysis (AREDS; Newsome
1988; VECAT). The trials were reasonably consistent (I2 = 28%)
(Analysis 3.1). Overall there was a beneficial effect of supplemen-
tation (pooled OR fixed-effect model 0.81, 95% CI 0.67 to 0.98,
P = 0.03). A random-effects model gave a different result (pooled
OR 0.83, 95% CI 0.63 to 1.09, P = 0.18). The difference in these
two models reflects the difference in weighting given to the largest
trial (AREDS): 75% in the fixed-effect model versus 63% in the
random-effects model.
Distance visual acuity: mean
Not all trials reported visual acuity data in a dichotomous format.
Some trials reported average distance visual acuity at the end of
the follow-up period or the mean change in visual acuity.
Seven trials contributed to this analysis (AMDSG; Bartlett 2007;
Kaiser 1995;Newsome1988;Newsome2008; Stur 1996;Veterans
LAST study). A total of 203 people were randomised to treatment
and 187 to control. There was considerable inconsistency in trial
results (I2 = 60%) (Analysis 3.2). There was little evidence of any
benefit of treatment.
Progression of AMD: dichotomous
Data on the progression of AMD were not reported or were re-
ported in such a way as to make it difficult to extract data for this
review in three studies (Kaiser 1995; Newsome 1988; Veterans
LAST study).
Four trials contributed data on the progression of AMD as a di-
chotomous outcome (AREDS; Holz 1993; Stur 1996; VECAT)
(Analysis 3.3). The results of the trials were inconsistent (I2 =
61%) with the ORs for the individual studies ranging from 0.50
to 2.31. Estimating a pooled OR, therefore, was not of value in
this case. Moreover, these trials were quite different in terms of the
interventions studied, follow-up period and method of evaluating
progression of AMD. (See Table 2).
Progression of AMD: continuous
Two trials reported the progression of AMD in a continuous for-
mat (AMDSG; Bartlett 2007), with 48 people randomised to
treatment and 32 to control (Analysis 1.2).
There was limited information from the Chinese trial (Wang
2004), particularly about the definitions of the outcome.However,
the authors reported that supplementation with zinc, vitamin E
and vitamin C over 24 months had no effect on the progression
of early AMD (Chi2 test P > 0.05) but had a beneficial effect
on the progression of the disease in people with advanced AMD.
Twelve of 124 people receiving supplements who had large drusen,
geographic atrophy or neovascularisation in one eye progressed
to “advanced AMD” (not defined but perhaps comparable to the
AREDS definitions) compared to 36/124 in the placebo group
(Chi2 P < 0.05).
Quality of life
CARMIS reported higher NEI VFQ-25 scores in the treated com-
pared to the non-treated group after 24 months. The mean change
in overall score at 24 months follow-up was 3.6 (95% CI 0.50 to
6.81) in the treated group and -8.7 (95% CI -16.54 to -0.97) in
the non-treated group.
Adverse effects
The main reported adverse effect leading to withdrawal from the
studies was gastrointestinal symptoms. Of 286 people randomised
into trials of zinc sulfate supplementation compared to placebo,
5/146 zinc-treated people withdrew due to gastrointestinal symp-
toms compared to 2/140 controls. No-one developed copper-defi-
ciency anaemia (high zinc intakes can inhibit copper absorption).
In AMDSG one person developed an “allergic reaction” although
it was not clear whether or not this was related to the treatment.
AREDS considered a number of safety outcomes. They conducted
over 100 comparisons of zinc versus no zinc and antioxidants ver-
sus no antioxidants. Participants in the antioxidant arms more
frequently reported yellow skin (8.3% versus 6.0%, P = 0.008).
Participants in the zinc arms reported more anaemia (13.2% ver-
sus 10.2%, P = 0.004), however, serum haematocrit levels were
the same. They found that participants taking zinc had a lower
mortality. Later follow-up of the cohort of people taking part in
the AREDS study found that there was a significant increase in
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hospital admissions due to genitourinary diseases in people taking
zinc supplements (11.1% versus 7.6% P = 0.0003) (AREDS).
There has been one published report on a small case series describ-
ing the presence of yellow rings in the cornea of people who had
been taking vitamin supplements (Eller 2012). The significance
of this is unclear at present.
The main ATBC trial found an increased risk of lung cancer as-
sociated with beta-carotene supplementation (ATBC), a finding
that was repeated in the large CARET trial (Omenn 1996). Beta-
carotene supplementation is contraindicated in people who smoke
or have been exposed to asbestos.
Huang 2006 did not identify any consistent adverse effects of min-
eral and vitamin supplements but only included nine RCTs in
their review. A subsequent Cochrane Review investigating antiox-
idant supplements for preventing all cause mortality, including 78
trials with 296,707 participants, concluded “We found no evidence
to support antioxidant supplements for primary or secondary preven-
tion. Beta-carotene and vitamin E seem to increase mortality, and so
may higher doses of vitamin A” (Bjelakovic 2012).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Zinc for age-related macular degeneration
Patient or population: patients with age-related macular degeneration
Settings: community
Intervention: zinc
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Zinc
Distance visual acuity
(loss of 3 or more lines)
LogMAR
Follow-up: mean 6.3
years
Moderate OR 0.81
(0.66 to 0.99)
1942
(2 studies)
⊕⊕⊕©
moderate1
300 per 1000 258 per 1000
(220 to 298)
Progression to advanced
AMD
Grading of fundus pho-
tographs
Follow-up: mean 6.3
years
Moderate OR 0.73
(0.58 to 0.93)
1943
(3 studies)
⊕⊕⊕©
moderate2
300 per 1000 238 per 1000
(199 to 285)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
AMD: age-related macular degeneration; CI: confidence interval; OR: odds ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.1
6
A
n
tio
x
id
a
n
t
v
ita
m
in
a
n
d
m
in
e
ra
l
su
p
p
le
m
e
n
ts
fo
r
slo
w
in
g
th
e
p
ro
g
re
ssio
n
o
f
a
g
e
-re
la
te
d
m
a
c
u
la
r
d
e
g
e
n
e
ra
tio
n
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
2
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
1 Downgraded for imprecision: wide confidence intervals and upper confidence limit is close to 1.
2 Downgraded for inconsistency: one study with OR of 2.31, overall I2 = 28%.
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Vitamin E for age-related macular degeneration
Patient or population: patients with age-related macular degeneration
Settings: community
Intervention: vitamin E
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Vitamin E
Distance visual acuity
(loss of 2 or more lines)
LogMAR
Follow-up: 4 years
Moderate OR 1.05
(0.71 to 1.54)
1179
(1 study)
⊕⊕©©
low1,2
100 per 1000 104 per 1000
(73 to 146)
Progression of AMD (di-
chotomous)
Grading of fundus pho-
tographs
Follow-up: 4 years
Moderate OR 1.11
(0.81 to 1.53)
997
(1 study)
⊕⊕©©
low1,2
200 per 1000 217 per 1000
(168 to 277)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
AMD: age-related macular degeneration; CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded for inconsistency: only one study so not possible to assess consistency between studies.
2 Downgraded for imprecision: wide confidence intervals comparable with benefit and harm.1
8
A
n
tio
x
id
a
n
t
v
ita
m
in
a
n
d
m
in
e
ra
l
su
p
p
le
m
e
n
ts
fo
r
slo
w
in
g
th
e
p
ro
g
re
ssio
n
o
f
a
g
e
-re
la
te
d
m
a
c
u
la
r
d
e
g
e
n
e
ra
tio
n
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
2
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Lutein for age-related macular degeneration
Patient or population: patients with age-related macular degeneration
Settings: community
Intervention: lutein
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Lutein
Distance visual acuity
(loss of 3 or more lines)
See comments Two relatively small trials
published. Currently data
on this outcome not avail-
able in a suitable format for
inclusion in this review
Progression of AMD (di-
chotomous)
See comments Two relatively small trials
published. Currently data
on this outcome not avail-
able in a suitable format for
inclusion in this review
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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D I S C U S S I O N
Summary of main results
The trials contributing to this review fall into two categories. There
are two large trials with reasonably long treatment duration and
follow-up of four to six years (AREDS; VECAT). The other 11
trials are smaller (ranging from 20 to 400 participants) and have
shorter duration of treatment and follow-up (six to 24 months).
The large trials provide reasonably clear answers to different ques-
tions. The AREDS trial provides evidence that long-term supple-
mentation with vitamins C, E, beta-carotene and zinc, in people
with age-related macular degeneration (AMD), reduced the risk
of progression of the disease and visual acuity loss. The overall
benefit is modest with a risk reduction in the order of 20% to
25%. However, given that treatment options for AMD are lim-
ited, and vision loss is rarely recovered, this is of interest to people
with AMD.
The VECAT study suggests that the general population should
not take vitamin E with a view to preventing the incidence or pro-
gression of AMD (Evans 2012). However, the study was under-
powered to answer the question as to whether people with signs
of AMD, such as those participating in the AREDS study, should
take vitamin E. Currently VECAT is the only published trial on
vitamin E supplementation and AMD.
The other trials of multivitamin preparations, Ocuguard (
AMDSG), Ocupower (Veterans LAST study), Visaline (Kaiser
1995) and lutein/antioxidant (Bartlett 2007) are too small to pro-
vide evidence either way or currently data are not available in a for-
mat suitable for inclusion in this review (CARMIS; LISA). Pool-
ing results, where possible, did not provide evidence of any benefit
of supplementation. However, these trials were of relatively short
duration.
A total of four trials investigated zinc supplementation (AREDS;
Holz 1993; Newsome 1988; Stur 1996) and one trial a novel zinc-
monocysteine formulation (Newsome 2008). The AREDS study
indicated that the beneficial effect of zinc supplementation was of
a similar order to that of vitamin supplementation. The other tri-
als provide more conflicting evidence. Newsome 1988 found a re-
duction in the risk of visual acuity loss with supplementation over
12 to 24 months. However, Stur 1996 found no effect of treat-
ment. Stur 1996, which was planned to recruit 500 participants,
was terminated early because the results of the first 40 patients at
24 months indicated no benefit of treatment. The other two trials
of zinc supplementation are as yet unpublished, although limited
results from Holz 1993 were published in abstract form and are
included here. Newsome 2008 found that zinc-monocysteine had
beneficial effects on visual acuity and contrast sensitivity. One un-
published trial on zinc supplementation for which data are un-
likely to be available has been excluded from the review (France
1998).
Overall completeness and applicability of
evidence
The main evidence that antioxidant vitamin and mineral supple-
mentation is of benefit comes from the AREDS trial. As AREDS
is a large, well-conducted randomised study, potential biases will
have been minimised. The only area where bias may have been
introduced is if there were different systemic effects of the antioxi-
dant and zinc supplementation (for example, yellowing of skin or
difficulty swallowing tablets) which led the participants to guess
which group they were in or alternatively, the retinal fundus pho-
tographs might have been different in some way such that the
graders response was affected by treatment group. However, this
is unlikely and there was little evidence that this was a problem in
the study.
It is worth comment that pooling data from trials other than
AREDS reveals little evidence for effectiveness of antioxidant vita-
min andmineral supplements on preventing visual loss or progres-
sion of the disease. However, the other studies encompass many
different formulations and in general were rather small and of short
duration which may explain the lack of effect.
AREDS was the only study to examine in detail the question of sa-
fety. They found little evidence of harm but there was an increased
risk of hospital admission due to genito-urinary complications in
people taking the zinc supplements. The safety of some of the com-
ponents of the AREDS formulation have been questioned in other
studies. Two large randomised controlled trials have indicated that
smokers who take beta-carotene may be at increased risk of devel-
oping lung cancer (ATBC; Omenn 1996). The Heart Outcomes
Prevention Evaluation (HOPE) Study found that, among people
with vascular disease or diabetes, vitamin E supplementation was
associated with a higher risk of heart failure (Lonn 2005). A sys-
tematic search of the literature for systematic reviews addressing
harms of vitamin supplements did not identify any further relevant
evidence. One small case series raised concerns about the presence
of yellow corneal rings associated with vitamin supplementation
(Eller 2012).
Quality of the evidence
As the majority of the trials were placebo-controlled we mostly
assessed them as being at low risk of bias. It was also often not clear
the extent to which attrition bias may have played a role. There
was some evidence of selective outcome reporting with respect to
data on visual acuity. We identified three trials that did not report
non-significant data. Another problem with visual acuity is the
variety of ways in which it can be reported - dichotomous with a
variety of potential cut-points, as a continuous variable reporting
change or final value. It is possible that investigators have done
analyses of visual acuity in a variety of ways and reported the
most significant finding. However, in these trials we did not find
evidence of improved visual acuity associated with treatment.
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Implications for practice
People with age-related macular degeneration (AMD) may expe-
rience modest delay in progression of the disease with antioxidant
vitamin and mineral supplementation. This finding is drawn from
one large trial conducted in a relatively well-nourished American
population. Until it is replicated by other large-scale trials in other
populations we will not know whether these findings can be ap-
plied more generally.
Antioxidant vitamin andmineral supplements are readily available
for purchase without prescription in many countries. The deci-
sion as to whether to take these supplements is at the discretion
of the person with AMD. The following benefits and harms need
to be considered. People with AMD may delay the progression
of their condition if they take antioxidant vitamins and zinc at
the levels described in this review. Given that there are few other
interventions that offer much in the way of disease prevention or
cure this is an important consideration. However, harmful effects
associated with long-term vitamin supplementation, particularly
in smokers and people with vascular disease, cannot be ruled out.
A healthy diet with a variety of fresh fruit and vegetables will have
many benefits and is unlikely to be harmful. It may be difficult,
however, to consume as part of a normal diet the levels of antiox-
idants and zinc described in the trials included in this review.
There is currently considerable interest in the potential role of
lutein and zeaxanthin supplementation in AMD. This review in-
cludes only two small trials on lutein, neither of which provides
good evidence for the effectiveness of such supplements.
Implications for research
Trials in other populations, preferably with a variety of nutritional
status, are required. These trials should have a large enough sample
size, and long enough duration, to demonstrate effects that are
meaningful for people and should also include outcomes relevant
to people affected by AMD including quality of life assessment. It
is likely that AMD develops over many years. Three categories of
people may be identified: healthy people at risk because of age or
genetic factors; people with early stages of the disease; people with
intermediate or late-stage disease. If antioxidant supplementation
is protective, there may be differences in the effect depending on
the stage of the disease.
Trial reporting should include enough information to assess the
role of selective outcome reporting bias (ideally by providing online
access to the protocol for the study) and clearer information about
follow-up of participants in the study, in particular reasons for
exclusion.
As antioxidant vitamin and mineral supplements have systematic
effects the literature on this topic would be much improved by a
systematic review of the potential harms of such products, includ-
ing broader sources of evidence than just randomised controlled
trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
AMDSG
Methods Method of allocation: sponsor prepared coded tablets
Masking: participant - not clear; provider - yes; outcome - yes
Losses to follow-up: 4 died (2 treatment, 2 control); 1 adverse effect withdrawn (treat-
ment); 7 lost to follow-up (1 treatment, 6 control)
Participants Country: USA
Number of participants randomised: 71 veterans
Age: average age 72 years
Sex: 66 male 5 female
Inclusion criteria: people with a monocular one line drop in Snellen visual acuity not
attributable to cataract, amblyopia, systemic or ophthalmic disease AND clinically ob-
servable drusen, RPE disruption and loss of macular reflex
Exclusion criteria: greater than 1 year use of vitamins, ex-prisoners of war, chronic
alcoholics with tobacco/nutritional amblyopia or gastrointestinal absorption disorders
Interventions Treatment: Ocuguard (Twin Lab Inc, Ronkonkoma, NY) broad-spectrum antioxidant:
beta-carotene 20,000 IU, vitamin E 200 IU, vitamin C 750 mg, citrus bioflavonoid
complex 125 mg, quercitin (bioflavonoid) 50 mg, bilberry extract (bioflavonoid) 5 mg,
rutin (bioflavonoid) 50 mg, zinc picolinate 12.5 mg, selenium 50 µg, taurine 100 mg,
n-acetyl cysteine 100 mg, l-glutathione 5 mg, vitamin B2 25 mg, chromium 100 µg
Control: starch placebo
Duration: 18 months
Outcomes Snellen acuity with best refraction converted to logMAR units for analysis; near vision
M units with dual sided Bailey-Lovie chart; contrast sensitivity; retinal grading score
(adapted from Chesapeake Bay Study); subjective perception of vision; adverse gastroin-
testinal reactions
Notes Treatment and placebo may not have been identical
Funders: Twin Laboratories Inc, Ronkokoma NY; Stereo Optical Inc, Chicago, IL; Eye
Communications Inc, Upland, CA; Illinois College of Optometry, Chicago, IL; Pa-
cific University College of Optometry, Forest Grove, OR; Ezell Foundation, American
Academy of Optometry, Rockville, MD
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Both the capsule for the placebo group
(starch) and the capsule for the antioxidant
group (Ocuguard) were formulated by Twin
Laboratores Inc., Ronkonkoma, NY. An in-
termediary company, Eye Communications,
Inc., Upland, CA. was responsible for assign-
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AMDSG (Continued)
ing and maintaining the identity of codes, la-
beling and distribution of masked bottles of
capsules to each DVA Medical Centre phar-
macy service” Part 1 page 14
“Group one and group two patients were
randomized between capsule number 1601
(starch placebo) and capsule number 1602
(Ocuguard) at each center by the optometrist
co-investigator. Neither the optometrist nor
the registered dietitian co-investigators nor the
veteran subject knew the identify of the cap-
sules.” Part 1 page 14
Allocation concealment (selection bias) Unclear risk “Both the capsule for the placebo group
(starch) and the capsule for the antioxidant
group (Ocuguard) were formulated by Twin
Laboratores Inc., Ronkonkoma, NY. An in-
termediary company, Eye Communications,
Inc., Upland, CA. was responsible for assign-
ing and maintaining the identity of codes, la-
beling and distribution of masked bottles of
capsules to each DVA Medical Centre phar-
macy service” Part 1 page 14
“Group one and group two patients were
randomized between capsule number 1601
(starch placebo) and capsule number 1602
(Ocuguard) at each center by the optometrist
co-investigator. Neither the optometrist nor
the registered dietitian co-investigators nor the
veteran subject knew the identify of the cap-
sules.” Part 1 page 14
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk “Both the capsule for the placebo group
(starch) and the capsule for the antioxidant
group (Ocuguard) were formulated by Twin
Laboratores Inc., Ronkonkoma, NY. An in-
termediary company, Eye Communications,
Inc., Upland, CA. was responsible for assign-
ing and maintaining the identity of codes, la-
beling and distribution of masked bottles of
capsules to each DVA Medical Centre phar-
macy service” Part 1 page 14
“Group one and group two patients were
randomized between capsule number 1601
(starch placebo) and capsule number 1602
(Ocuguard) at each center by the optometrist
co-investigator. Neither the optometrist nor
the registered dietitian co-investigators nor the
veteran subject knew the identify of the cap-
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AMDSG (Continued)
sules.” Part 1 page 14
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk “Both the capsule for the placebo group
(starch) and the capsule for the antioxidant
group (Ocuguard) were formulated by Twin
Laboratores Inc., Ronkonkoma, NY. An in-
termediary company, Eye Communications,
Inc., Upland, CA. was responsible for assign-
ing and maintaining the identity of codes, la-
beling and distribution of masked bottles of
capsules to each DVA Medical Centre phar-
macy service” Part 1 page 14
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk “Both the capsule for the placebo group
(starch) and the capsule for the antioxidant
group (Ocuguard) were formulated by Twin
Laboratores Inc., Ronkonkoma, NY. An in-
termediary company, Eye Communications,
Inc., Upland, CA. was responsible for assign-
ing and maintaining the identity of codes, la-
beling and distribution of masked bottles of
capsules to each DVA Medical Centre phar-
macy service” Part 1 page 14
“Group one and group two patients were
randomized between capsule number 1601
(starch placebo) and capsule number 1602
(Ocuguard) at each center by the optometrist
co-investigator. Neither the optometrist nor
the registered dietitian co-investigators nor the
veteran subject knew the identify of the cap-
sules.” Part 1 page 14
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk “Both the capsule for the placebo group
(starch) and the capsule for the antioxidant
group (Ocuguard) were formulated by Twin
Laboratores Inc., Ronkonkoma, NY. An in-
termediary company, Eye Communications,
Inc., Upland, CA. was responsible for assign-
ing and maintaining the identity of codes, la-
beling and distribution of masked bottles of
capsules to each DVA Medical Centre phar-
macy service” Part 1 page 14
“Group one and group two patients were
randomized between capsule number 1601
(starch placebo) and capsule number 1602
(Ocuguard) at each center by the optometrist
co-investigator. Neither the optometrist nor
the registered dietitian co-investigators nor the
veteran subject knew the identify of the cap-
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AMDSG (Continued)
sules.” Part 1 page 14
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 17 patients withdrew from the study over
18 months. 4 patients died. 1 patient expe-
rienced an idiosyncratic reaction and was
dropped. Attritiondatawere as follows: “71
patients at baseline, 67 patients at 6 m, 59
patients at 12m, 59 patients at 18m.” Sim-
ilar numbers of drop outs from groups 1
and 2
Selective reporting (reporting bias) Unclear risk Difficult to assess with the information
given
AREDS
Methods Method of allocation: coded bottles
Masking: participant - yes; provider - yes; outcome - yes
Losses to follow-up: 2.4% balanced across study groups
Participants Country: USA
Number of participants randomised: 3640
Age: average age 69 years (range 55 to 80)
Sex: 56% female
Inclusion criteria: 20/32 or better in at least 1 eye; ocular media clear and therefore able
to obtain adequate stereoscopic fundus photographs; at least 1 eye free from eye disease
that could complicate assessment of AMD
Exclusion criteria: Illness or disorders that would make long-term follow-up or compli-
ance with study protocol unlikely or difficult
Interventions Treatment: antioxidants (500 mg vitamin C, 400 IU vitamin E, 15 mg beta-carotene),
zinc (80 mg of zinc as zinc oxide and 2 mg of copper as cupric oxide)
Control: placebo identical in external appearance and similar in internal appearance and
taste
Duration: 7 years
Outcomes Primary outcomes: (1) progression to advanced AMD and (2) 15 letter or more decrease
in visual acuity score. AMD assessed using stereoscopic fundus colour photograph; vi-
sual acuity measured using EDTRS logMAR chart. Safety outcomes included: reported
adverse events; serum levels of haemoglobin; hospitalisations and mortality
Notes 2 x 2 factorial design. 67% participants took additional supplements to RDA levels
(Centrum). In 1996 current smokers offered option of discontinuing supplementation;
2% of participants and 18% of smokers did so. A further 2.3% reassigned to no beta-
carotene group. Intention-to-treat analysis maintained
Risk of bias
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AREDS (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Simple randomization, stratified by clinical
center and AMD category, was used to as-
sign treatment. Participants in Categories 2,
3, and 4 were assigned with probability one
quarter to each treatment group” AREDS re-
port number 8, randomisation
“Multiple unique bottle codes were randomly
assigned to each of the 4 treatments for Cat-
egories 2, 3, and 4, and also to each of the 2
treatments for participants in Category 1. A
bottle code corresponding to the assigned treat-
ment was randomly selected for each partici-
pant”. AREDS report number 8, randomi-
sation
Allocation concealment (selection bias) Low risk “Multiple unique bottle codes were randomly
assigned to each of the 4 treatments for Cat-
egories 2, 3, and 4, and also to each of the 2
treatments for participants in Category 1. A
bottle code corresponding to the assigned treat-
ment was randomly selected for each partici-
pant”. AREDS report number 8, randomi-
sation
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk “The 4 treatment interventions were double-
masked...” AREDS report number 8, study
design.
“Study medication tablets for the 4 treatment
groups were identical in external appearance
and similar in internal appearance and taste.
The coordinating center was custodian of the
treatment code” AREDS report number 8,
masking
“Four participants (0.1%) were reported
to have been unmasked during the trial”
AREDS report number 8, data quality
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk “The 4 treatment interventions were double-
masked...” AREDS report number 8, study
design.
“Study medication tablets for the 4 treatment
groups were identical in external appearance
and similar in internal appearance and taste.
The coordinating center was custodian of the
treatment code” AREDS report number 8,
masking
“Four participants (0.1%) were reported
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AREDS (Continued)
to have been unmasked during the trial”
AREDS report number 8, data quality
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk “Visual acuity was assessed by certified ex-
aminers using the ETDRS logMAR chart
and a standardized refraction and visual acu-
ity protocol (AREDS Manual of Operations;
The EMMES Corporation, Rockville, Md)
” AREDS report number 8, study popula-
tion
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk “Stereoscopic fundus photographs of the mac-
ula were taken at baseline and annually
beginning 2 years after randomization and
graded centrally using standardized grading
procedures.” AREDS report number 8, pro-
cedures
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Participants without photographic or visual
acuity follow-upwere evenly distributed across
treatment groups.” AREDS report number
8, enrolment and patient characteristics
“Only 2.4% of AREDS participants were lost
to follow-up (missed at least their last 2 con-
secutive visits). Losses to follow-up were bal-
anced across treatment groups” AREDS re-
port number 8, data quality.
“Of almost 50000 possible follow-up visits,
10% were missed. The frequency of missed
visits and mean follow-up time (6.3 years)
did not differ by treatment group. Most par-
ticipants (90%) had at least 5 years of follow-
up.” AREDS report number 8, data quality
Selective reporting (reporting bias) Low risk “At the start of the study, 2 primary outcomes
were defined for study eyes in the AMD trial:
(1) progression to advanced AMD and (2) at
least a 15-letter decrease in visual acuity score.
” AREDS report number 8, outcomes
Bartlett 2007
Methods Method of allocation: sponsor prepared coded tablets
Masking: participant - yes; provider - yes; outcome - yes
Losses to follow-up: 5 (2 treatment, 3 control)
Participants Country: UK
Number of participants randomised: 30
Age: 55 to 82 years; average age 69.2 (SD 7.8)
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Bartlett 2007 (Continued)
Sex: 53% female
Inclusion criteria:
(1) Provide written informed consent
(2) Be available to attend one of the research centres
(3) Present with no ocular pathology in at least 1 eye, or no ocular pathology other than
soft or hard drusen, and areas of increased or decreased pigment associated with drusen.
Fundus examination was used to determine the presence of AMD
Exclusion criteria: type I and II diabetes, prescribed antiplatelet or anticoagulant medi-
cation, and concurrent use of nutritional supplements. Those with advanced AMD in 1
or both eyes were excluded
Interventions Treatment: supplement contained: lutein esters (6 mg);retinol (750 mg); vitamin C (250
mg); vitamin E (34 mg); zinc (10 mg); copper (0.5 mg)
Control: the placebo tablets contained cellulose
Duration: 9 months
Outcomes Trial report provided data on contrast sensitivity at 9 months follow-up. Protocol listed
more outcomes (see below under selective reporting) and specified 9 and 18 months
follow-up
Notes Sample size calculations reported in trial report: “A group size of nine was calculated to be
sufficient to provide 80% power at the 5% significance level for CS based on an effect size
of 0.3 log units, and mean and standard deviation (s.d.) values taken from a sample of 50
ARM and atrophic AMD patients of the University optometry clinic (1.3970.22 log CS).”
Bartlett 2007
Sample size calculations reported in protocol paper “From initial data collection we have
calculated the treatment group sizes required in order to have 80% power at the 5% sig-
nificance level for VA, CS, MM test, and the EMS. These values suggest that a total of 63
normal, and 96 age-related macular disease participants are required.” Bartlett 2003
http://www.controlled-trials.com/ISRCTN78467674
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The random number generator function in
Microsoft Excel is being used to allocate par-
ticipants to µ and λ groups. Odd numbers
allocate to the µ group” Bartlett 2003 (pro-
tocol report) page 3
“Only one investigator (HB) was involved in
the randomization process, which employed
the random number generator in Microsoft
Excel for Windows XP. Odd and even num-
bers were used to identify group.” Bartlett
2007, page 1122
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Bartlett 2007 (Continued)
Allocation concealment (selection bias) Low risk “Enrolment was carried out by HB, who,
along with FE, was masked to group assign-
ment.” Bartlett 2007, page 1121
“Only one investigator (HB) was involved in
the randomization process, which employed
the random number generator in Microsoft
Excel for Windows XP. Odd and even num-
bers were used to identify group.” Bartlett
2007, page 1122
“Investigators and participants do not know
which symbol represents the placebo tablets,
and which represents the active formulation.
” Bartlett 2003 (protocol report) page 3
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk “The study formulation and placebo tablets
have been produced by Quest Vitamins Ltd,
Aston Science Park, Birmingham, B7 4AP,
and are identical in external and internal ap-
pearance, and taste. The manufacturer has
allocated distinguishing symbols, µ and λ.
The tablets are packaged in identical, sealed,
white containers; the only difference being the
symbol on the label. Investigators and partic-
ipants do not know which symbol represents
the placebo tablets, and which represents the
active formulation.” Bartlett 2003 (protocol
report) page 3
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk Not reported
Blinding of outcome assessment (detection
bias)
Visual acuity
Unclear risk “The study formulation and placebo tablets
have been produced by Quest Vitamins Ltd,
Aston Science Park, Birmingham, B7 4AP,
and are identical in external and internal ap-
pearance, and taste. The manufacturer has
allocated distinguishing symbols, µ and λ.
The tablets are packaged in identical, sealed,
white containers; the only difference being the
symbol on the label. Investigators and partic-
ipants do not know which symbol represents
the placebo tablets, and which represents the
active formulation.” Bartlett 2003 (protocol
report) page 3
“End of trial assessment using questionnaires
indicated‘masking success. Out of those par-
ticipants taking the placebo tablet, 10% cor-
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Bartlett 2007 (Continued)
rectly guessed which tablet they were taking,
and 10% incorrectly guessed. Out of those
taking nutritional supplement, 13% guessed
correctly which tablet they were taking, and
7% incorrectly guessed. The remaining par-
ticipants did not know which group they were
randomized to.”
Blinding of outcome assessment (detection
bias)
Progression AMD
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Statistical analysis was carried out on a per
protocol basis.”
Selective reporting (reporting bias) High risk Protocol report: following outcomes listed:
visual acuity, contrast sensitivity, colour vi-
sion, macular mapping test, glare recovery,
fundus photographs analysed by colour and
edge analysis software
Trial report only contrast sensitivity (CS)
reported: “Outcome measure CS was mea-
sured using a Pelli-Robson chart (Clement
Clarke International, Edinburgh Way, Har-
low, Essex, CM20 2TT, UK) and scored per
letter.”
CARMIS
Methods Method of allocation: random list, unclear how delivered
Masking: participant - no; provider - no; outcome - unclear
Losses to follow-up: 18% in supplement group, 38% in no supplement group
Participants Country: Italy
Number of participants randomised: 145
Age: average 73 years
Sex: 58 men; 87 women
Inclusion criteria:
AREDS category 3 features (non advanced AMD)
• Visual acuity >= 20/32 (0.2 logMAR, 74 letters of ETDRS chart)
• Extensive (as measured by drusen area) intermediate (63 m, 125 m) drusen
• At least 1 large (125 m) drusen or geographic atrophy not involving the centre of
the macula
Exclusion criteria:
• Visual acuity < 20/32
• Advanced AMD in 1 or both eyes
• Other ocular disease with irreversible reduction in visual acuity
• Lens opacity
• Insufficient pupil dilation
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CARMIS (Continued)
• Previous laser treatment at posterior pole
• Macular changes not due to AMD
• Intolerant to carotenoids
• Major chronic disease/life expectancy < 6 months
• No informed consent
• In other experimental study
Interventions Treatment: oral daily supplementation of vitamin C (180 mg), vitamin E (30 mg), zinc
(22.5 mg), copper (1 mg), lutein (10 mg), zeaxanthin (1 mg) and astaxanthin (4 mg;
AZYR SIFI, Catania, Italy)
Control: no dietary supplementation
Duration: 24 months
Outcomes Best-corrected visual acuity (ETDRS, logMAR), intraocular pressure, fundus examina-
tion and contrast sensitivity at baseline, 6, 12 and 24 months
NEI VFQ: baseline, 12 and 24 months
Multi-focal electroretinograms (ERG) at 6 and 12 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A permuted blocks allocation scheme was
used to perform this random allocation” Page
3
Allocation concealment (selection bias) Unclear risk “A 24-month prospective open-label random-
ized study... ” Page 2
“The study coordinator allocated study num-
bers sequentially, as participants were en-
rolled. Participants were then randomly allo-
cated to the treatment or no treatment group.
A permuted blocks allocation scheme was used
to perform this random allocation. The allo-
cation list was stored at a remote site.” Page
2/3
“Study drug was administered by an un-
masked physician who had no other role in
the study.” Page 2
No mention was made of allocation ra-
tios but 103 people recruited to treatment
group and 42 to no treatment group
Blinding of participants and personnel
(performance bias)
Visual acuity
High risk “A 24-month prospective open-label random-
ized study... ” Page 2
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CARMIS (Continued)
Blinding of outcome assessment (detection
bias)
Visual acuity
High risk “A 24-month prospective open-label random-
ized study... ” Page 2
“In order to allow for an unbiased assessment
of VA and ancillary study measures, an in-
dependent physician was assigned the role of
masked evaluator.” Page 2
However, as patients were not masked this
could have affected the measurement of vi-
sual acuity
Incomplete outcome data (attrition bias)
All outcomes
High risk “Nineteen people in the group T-AMD, and
16 subjects from the group NT-AMD, were
excluded from final data analysis.” Page
4. This exclusion was uneven between 2
groups: 19/103 (18.4%) and 16/42 (38.
1%) and also inconsistent with the data
in table III, page 6. In table III 14 people
withdrew from the carotenoids group and 3
from the control group; 20 people discon-
tinued the intervention in the carotenoids
group and 17 in the control group
Selective reporting (reporting bias) Unclear risk Unclear. Did fundus examination but did
not report progression of AMD
Holz 1993
Methods Method of allocation: not known
Masking: participant - yes; provider - yes; outcome - yes
Losses to follow-up: not known
Participants Country: UK
Number of participants randomised: 58
Age: 55 to 82, mean 68
Interventions Treatment: 100 mg zinc sulfate twice daily
Control: placebo
Duration: 12 to 24 months
Outcomes Visual acuity; contrast sensitivity; dark adaptation; stereo fundus photographs and flu-
orescein angiograms
Notes Data available from abstract only
Risk of bias
Bias Authors’ judgement Support for judgement
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Holz 1993 (Continued)
Random sequence generation (selection
bias)
Unclear risk “randomized double-blind study”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
Visual acuity
Unclear risk “randomized double-blind study”
Blinding of participants and personnel
(performance bias)
Progression AMD
Unclear risk “randomized double-blind study”
Blinding of outcome assessment (detection
bias)
Visual acuity
Unclear risk “randomized double-blind study”
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk “randomized double-blind study”
“Stereo fundus photographs and fluorescein
angiograms were analyzed by investigators in
a masked fashion using a standardized grad-
ing scheme”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) High risk For visual acuity, trial report states that out-
come was analysed but only reports that re-
sult was not significant
Kaiser 1995
Methods Method of allocation: sponsor prepared coded tablets
Masking: participant - yes; provider - yes; outcome - yes
Losses to follow-up: none
Participants Country: Switzerland
Number of participants randomised: 20
Age: over 50; average age 72 in treatment group, 74 in control group
Sex: 7 male, 20 female
Inclusion criteria: people with non serous AMD. All participants had regional atrophy
of the pigment epithelium. Corrected visual acuity was between 20/100 and 20/25 with
distance correction of less than 4 dioptres.
Exclusion criteria: people with diabetes mellitus, endocrine problems, cardiac dysrhyth-
mia, cardial infarction or hypotension, other ocular disorders
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Kaiser 1995 (Continued)
Interventions Treatment: Visaline (Novopharma Cham, Switzerland). Each tablet contains 1.5 mg
buphenine HCl, 10 mg beta-carotene, 10 mg tocopherol acetate and 50 mg ascorbic
acid. Participants took 2 tablets in the morning and at night, daily except for Saturdays
and Sundays.
Control: placebo resembling active treatment prepared by sponsor
Duration: 6 months
Outcomes Only 1 eye per person was evaluated. In cases of bilateral AMD, the eye with better visual
acuity was selected
Distance and near visual acuity; intraocular pressure; visual fields; lens opacity; retinal
visual acuity; colour vision; contrast sensitivity
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sequence generation not described in the
report but contact with investigator “The
allocation schedule was generated by the com-
pany and treatment schedule was concealed
from people enrolling patients.”
Allocation concealment (selection bias) Low risk Allocation concealment not described in
the report but contact with investigator
“The allocation schedule was generated by the
company and treatment schedule was con-
cealed from people enrolling patients.”
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk Study was placebo-controlled. Placebo not
described in the report but investigator re-
ported that “The placebo was also prepared
by the company and tablets resembled the ac-
tive treatment.”
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk Study was placebo-controlled. Placebo not
described in the report but investigator re-
ported that “The placebo was also prepared
by the company and tablets resembled the ac-
tive treatment.”
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk Study was placebo-controlled. Placebo not
described in the report but investigator re-
ported that “The placebo was also prepared
by the company and tablets resembled the ac-
tive treatment.”
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Kaiser 1995 (Continued)
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk Study was placebo-controlled. Placebo not
described in the report but investigator re-
ported that “The placebo was also prepared
by the company and tablets resembled the ac-
tive treatment.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 20 patients enrolled and 20 followed up
Selective reporting (reporting bias) Unclear risk Difficult to assess with the information
available
LISA
Methods Method of allocation: 2:1 intervention: control
Masking: participant - yes; provider - yes; outcome - yes
Losses to follow-up:
Participants Country: Austria
Number of participants randomised: 126
Age: over 50; average age 72
Sex: 50 male, 66 female
Inclusion criteria: people in categories 2, 3, or 4, according to the AREDS grading
scheme, aged 50 to 90 years with clear nonlenticular ocular media and visual acuity > 0.
4.
Exclusion criteria: primary retinal pigment epitheliumatrophy 125m,moderate or severe
nonproliferative diabetic retinopathy, proliferative diabetic retinopathy, participation in
a clinical trial in the 3 weeks preceding the study, ocular surgery within the last 6 months,
and a history of treatment with photosensitizing drugs
Interventions Treatment: Lutein (Lutamax DUO; Pharmaselect, Vienna, Austria) . The dosage in
months 1 to 3 was 20 mg once daily and in months 4 to 6 was 10 mg once daily
Control: placebo
Duration: 6 months
Outcomes Only one eye per person was included in the trial; if both eyes were eligible, one eye was
selected randomly
Macular pigment optical density
Distance visual acuity (ETDRS chart) and fundus photographs taken
Notes clinicaltrials.gov/ct2/show/NCT00879671
Risk of bias
Bias Authors’ judgement Support for judgement
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LISA (Continued)
Random sequence generation (selection
bias)
Unclear risk “The randomization of lutein (Lutamax
DUO; Pharmaselect, Vienna, Austria) ver-
sus placebo was 2:1, resulting in a total of 84
patients in the lutein group and 42 patients
in the placebo group” Page 8175
Allocation sequence generation not de-
scribed
Allocation concealment (selection bias) Unclear risk No description of allocation concealment.
However states ‘double masked’
Blinding of participants and personnel
(performance bias)
Visual acuity
Unclear risk “All subjects were asked to bring their study
medication to all visits, to allow compliance
testing by tablet counting.” Page 8175
Nodescription of placebo. Potential for un-
masking as to intervention received
No specific information provided as to the
blinding of outcome assessors (grading of
fundus images, assessment of MPOD or
visual function)
Blinding of outcome assessment (detection
bias)
Visual acuity
Unclear risk “All subjects were asked to bring their study
medication to all visits, to allow compliance
testing by tablet counting.” Page 8175
Nodescription of placebo. Potential for un-
masking as to intervention received
No specific information provided as to the
blinding of outcome assessors (grading of
fundus images, assessment of MPOD or
visual function)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 10/84 (11.9%) people in the lutein group
were lost to follow-up. In two people,
the withdrawal was due to serious adverse
events. One participant had a myocardial
infarction, and the other subject developed
CNV in the study eye
6/42 (14.3%) people in the placebo group
were lost to follow-up. One person devel-
oped CNV, which was again classified as a
serious adverse event
In patients who were lost to follow-up the
last observation was carried forward
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LISA (Continued)
Selective reporting (reporting bias) Unclear risk Difficult to assess with the information
available.
Newsome 1988
Methods Method of allocation: computer-generated table of random numbers
Masking: participant - yes; provider - yes; outcome - yes
Losses to follow-up: 23 (10 treatment, 13 placebo)
Participants Country: USA
Number of participants randomised: 174
Age: 42 to 89
Sex: 61 men 113 women
Inclusion criteria: macular degeneration: clinically visible drusen with varying degrees
of pigmentary change with visual acuity in 1 eye of 20/80 or better
Exclusion criteria: cataract reducing vision more than one line; other known serious
eye disease; diabetes mellitus; other known systematic/metabolic disease or congenital
condition which might interfere with results
Interventions Treatment: zinc sulfate 100 mg twice daily
Control: identical tablets with lactose and fructose
Duration: 1 to 2 years
Outcomes Pinhole corrected visual acuity using ETDRS charts; changes in visible pigment, drusen
or atrophy from grading of macular photographs; adverse effects of zinc including copper
deficiency anaemia
Notes Funders: Research Fund, Department of Veterinary Science, Utah State University, Lo-
gan; James L Shupe, DVM; Mary Katherine Peterson Foundation, Houston
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Subjects were randomly assigned [...] using
a computer-generated table of random num-
bers.” page 193
Allocation concealment (selection bias) Low risk “Subjects were randomly assigned to receive ei-
ther zinc or placebo [...]. The individual who
recorded the zinc-treated or placebo group as-
signment maintained personal control over
the randomization sheet and participated in
no other phases of the study. This individual
also handed the study tablets to subjects. All
other personnel were masked to the study.”
page 193
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Newsome 1988 (Continued)
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk “All other personnel were masked to the study.
” page 193
“Zinc sulfate was prepared as white tablets
containing 100 mg of United States Pharma-
copeia-graded material. Identical-appearing
tablets containing lactose and fructose served
as the placebo. All tablets were bottled in iden-
tical containers.” page 193
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk “All other personnel were masked to the
study.” page 193
“Zinc sulfate was prepared as white tablets
containing 100 mg of United States Phar-
macopeia-graded material. Identical-ap-
pearing tablets containing lactose and fruc-
tose served as the placebo. All tablets were
bottled in identical containers.” page 193
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk “All visual acuities were determined by one of
two masked observers throughout the study”
page 192
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk “Two independent observers masked as to pa-
tient identity,...” page 193
Incomplete outcome data (attrition bias)
All outcomes
Low risk “A total of 90 subjects [...] were randomized to
zinc and 84 subjects [...] to placebo. [......]. A
total of ten subjects were lost to follow-up from
the zinc-treated group and 13 subjects from
the placebo group. [...] This figure represents
dropout rates of 11.1% and 15.4% from the
zinc-treated and placebo groups, respectively”
page 193
Reasons for loss to follow-up zinc/placebo
(page 194 table 1)
• Stopped taking pills 5/6
• Started taking zinc 1/2
• Gastrointestinal symptoms 1/0
• Died 2/1
• Poor compliance 0/1
• Developed diabetes mellitus 0/1
• Unavailable 1/2
Selective reporting (reporting bias) High risk “Other ocular functions assessed included oc-
ular vision and photostress recover tests (These
observations are being analysed and will be
reported later)” page 193
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Newsome 2008
Methods Method of allocation: random allocation using a 50% likelihood scheme
Masking: participant - yes; provider - yes; outcome - yes
Losses to follow-up: 6, 3 in each group of 40 participants
Participants Country: USA
Number of participants randomised: 80
Age: average age 73.7 years
Sex: 59/74 female
Inclusion criteria:
• Presence of macular drusen with or without pigment changes
Exclusion criteria:
• Choroidal neovascular activity
• Any condition preventing view of the fundus
• Other conditions affecting eye: diabetes, eye surgery (except cataract). Chronic
open angle glaucoma with stable intraocular pressures and visual fields was allowed.
Both ZMCand placebo groups enrolled 40 participants, with best-corrected visual acuity
20/25 to 20/70, macular drusen, and pigment changes
Interventions Treatment: zinc-monocysteine 25 mg twice a day for 6 months
Control: placebo
Duration: 6 months
Outcomes Masked personnel determined baseline, 3- and 6-month best-corrected visual acuity,
contrast sensitivity and light flash recovery time
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A total of 80 subjects (40 per group) volun-
teered for the study and were randomized us-
ing a 50% likelihood scheme.” Page 593
Allocation concealment (selection bias) Low risk “An unmasked co-ordinator gave subjects,
upon enrollment, study materials in num-
bered containers using the randomization
scheme. This individual performed no data
collection.” Page 593
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk “Study materials were in tinted pharmaceu-
tical capsules that provided an indistinguish-
able appearance between ZMC and the plant
cellulose placebo.” Page 593
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk
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Newsome 2008 (Continued)
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk “Functional assessment....by masked trained
examiners...” Page 593
“Masked examiners determined contrast sen-
sitivity....” Page 593
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Thirty-seven [out of 40] in each group com-
peted all visits...” Page 593
Reasons for drop-out: 2 of placebo group
died from pre-existing medical conditions;
the rest of the dropouts (n = 4) were due to
gastrointestinal-related complaints
Selective reporting (reporting bias) Unclear risk Difficult to assess with the information
available
Stur 1996
Methods Method of allocation: sponsor prepared coded bottles
Masking: participant - yes; provider - yes; outcome - yes
Losses to follow-up: 6 withdrawn due to adverse gastrointestinal effects (4 treatment, 2
control); 14 withdrawn when developed neovascularisation (9 treatment, 5 control); 14
lost to follow-up (6 treatment, 8 control)
Participants Country: Austria
Number of participants randomised: 112
Age: 50 plus
Sex: 48 men, 64 women
Inclusion criteria: exudative AMD in 1 eye (defined as angiographic evidence of classic
or occult choroidal neovascularisation or RPE detachment) and early ARM with visual
acuity 20/40 or better in other eye (early ARM: macular drusen with no angiographic
evidence of exudative lesion)
Exclusion criteria: dense senile cataract; any other eye disease which could produce
significant and permanent loss of visual acuity during follow-up; physical status that
could prevent follow-up; history of serious systemic or metabolic disease
Interventions Treatment: zinc sulfate 200 mg once daily. Lemon flavoured effervescent tablet made of
citric acid containing saccharine and sorbitol.
Control: as treatment but without zinc sulfate
Duration: 24 months
Outcomes Best-corrected LogMAR visual acuity measured using Bailey-Lovie chart; contrast sensi-
tivity; incidence of choroidal neovascularisation; progression of disease (Wisconsin Age-
related Maculopathy Grading System); copper deficiency anaemia
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Stur 1996 (Continued)
Notes A priori sample size estimate was 500 patients but trial stopped early because interim
analysis showed no detectable trend
Funders: Astra, Linz, Austria; Austrian Foundation for the Propagation of Scientific
Research
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “This was a double-masked, randomized,
placebo-controlled study conducted at a single
center. The randomization between zinc and
placebo was performed in a ratio 1:1” Page
1228
No details provided of method of sequence
generation, however since coding provided
by sponsor this is unlikely to be a source of
bias
Allocation concealment (selection bias) Low risk “Coded doses of zinc sulfate and placebo were
prepared by the sponsor (Astra, Linz, Austria)
. All doses were lemon-flavored effervescent
tablets made of citric acid that provided im-
proved gastrointestinal absorption and con-
tained saccharine and sorbitol. Treatment
group doses contained an additional 200 mg
of zinc sulfate. (This preparation is identi-
cal to a zinc sulfate preparation registered in
Austria and other European countries under
the name Solvezink; Astra, Wedel, Germany.
) Tablets were bottled in identical containers.
” Page 1227, 1228
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk “Coded doses of zinc sulfate and placebo were
prepared by the sponsor (Astra, Linz, Austria)
. All doses were lemon-flavored effervescent
tablets made of citric acid that provided im-
proved gastrointestinal absorption and con-
tained saccharine and sorbitol. Treatment
group doses contained an additional 200 mg
of zinc sulfate. (This preparation is identi-
cal to a zinc sulfate preparation registered in
Austria and other European countries under
the name Solvezink; Astra, Wedel, Germany.
) Tablets were bottled in identical containers.
” Page 1227, 1228
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Stur 1996 (Continued)
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk “Coded doses of zinc sulfate and placebo were
prepared by the sponsor (Astra, Linz, Austria)
. All doses were lemon-flavored effervescent
tablets made of citric acid that provided im-
proved gastrointestinal absorption and con-
tained saccharine and sorbitol. Treatment
group doses contained an additional 200 mg
of zinc sulfate. (This preparation is identi-
cal to a zinc sulfate preparation registered in
Austria and other European countries under
the name Solvezink; Astra, Wedel, Germany.
) Tablets were bottled in identical containers.
” Page 1227, 1228
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk “Coded doses of zinc sulfate and placebo were
prepared by the sponsor (Astra, Linz, Austria)
. All doses were lemon-flavored effervescent
tablets made of citric acid that provided im-
proved gastrointestinal absorption and con-
tained saccharine and sorbitol. Treatment
group doses contained an additional 200 mg
of zinc sulfate. (This preparation is identi-
cal to a zinc sulfate preparation registered in
Austria and other European countries under
the name Solvezink; Astra, Wedel, Germany.
) Tablets were bottled in identical containers.
” Page 1227, 1228
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk “Coded doses of zinc sulfate and placebo were
prepared by the sponsor (Astra, Linz, Austria)
. All doses were lemon-flavored effervescent
tablets made of citric acid that provided im-
proved gastrointestinal absorption and con-
tained saccharine and sorbitol. Treatment
group doses contained an additional 200 mg
of zinc sulfate. (This preparation is identi-
cal to a zinc sulfate preparation registered in
Austria and other European countries under
the name Solvezink; Astra, Wedel, Germany.
) Tablets were bottled in identical containers.
” Page 1227, 1228
Incomplete outcome data (attrition bias)
All outcomes
High risk “One hundred twelve patients were enrolled
between March 1, 1990 and June 30, 1992.
Six patients (four in the treatment group, two
in the placebo group) could not tolerate the
medication because of gastrointestinal side ef-
fects and had to be withdrawn from the study.
Fourteen patients did not return for the sched-
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Stur 1996 (Continued)
uled follow-up visits or decided to withdraw
from the study because of personal reasons.
The withdrawal of these 14 patients was not
connected to any side effects of the study med-
ication. The rest of the recruited patients (92
patients) returned for all required visits.”Page
1229
“During the treatment period, a CNV devel-
oped in the study eye in 14 patients (nine in
the treatment group, five in the placebo group)
. Ten of these patients underwent laser treat-
ment and were withdrawn from the study.”
Page 1229
Selective reporting (reporting bias) Unclear risk Difficult to assess with the information
available
VECAT
Methods Method of allocation: coded bottles
Masking: participant - yes; provider - yes; outcome - yes
Losses to follow-up: not known
Participants Country: Australia
Number of participants randomised: 1204
Age: 55 to 80, mean 66
Sex: 56% female
Inclusion criteria: lens and retina of at least 1 eye available for documentation
Exclusion criteria: previous cataract surgery or advanced cataract in both eyes; steroid or
anticoagulation use; serious disease; regular use or sensitivity to vitamin E
Interventions Vitamin E 500 IU per day: natural vitamin E in soybean oil medium
Control: placebo identical in sight, taste and smell
Duration: 4 years
Outcomes 2m logMAR visual acuity; clinical examination; colour stereoscopic fundus photographs
graded using International Grading Scheme
Notes Worse eye used as the study eye
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Participants were then randomly allocated
to treatment group. This random allocation
was performed by using a “permuted blocks”
allocation scheme.” Page 2 of online article
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VECAT (Continued)
Allocation concealment (selection bias) Low risk “Study numbers were allocated sequentially
by the study coordinator as participants were
enrolled in the study.” Page 2of online article
“Bulk medications were dispensed into la-
belled jars by a person not involved in the
study. Vitamin E and placebo were dispensed
on different days to avoid confusion. Identical
containers were used. The jars were packed in
numerical order and then dispensed by study
personnel.” Page 2 of online article
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk “VitaminEand placebo capsules were of iden-
tical appearance and taste. Neither study staff
nor examiners or participants were aware of
the treatment allocation, although all knew
that participants would be randomly assigned
to receive either vitamin E or placebo.” Page
2 of online article
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk “VitaminEand placebo capsules were of iden-
tical appearance and taste. Neither study staff
nor examiners or participants were aware of
the treatment allocation, although all knew
that participants would be randomly assigned
to receive either vitamin E or placebo.” Page
2 of online article
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk “VitaminEand placebo capsules were of iden-
tical appearance and taste. Neither study staff
nor examiners or participants were aware of
the treatment allocation, although all knew
that participants would be randomly assigned
to receive either vitamin E or placebo.” Page
2 of online article
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk “VitaminEand placebo capsules were of iden-
tical appearance and taste. Neither study staff
nor examiners or participants were aware of
the treatment allocation, although all knew
that participants would be randomly assigned
to receive either vitamin E or placebo.” Page
2 of online article
“At the end of the study we reassessed the ini-
tial and final photographs for any change with
a “side by side” comparison in a masked and
randomised fashion.” Page 2 of online arti-
cle
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VECAT (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 78/595 (13%) participants in vitamin E
group and 72/598 (12%) of placebo group
withdrawn over the course of the study.
Reasons for withdrawal reported (table 3
and figure 3). Page 4 of online article.
Selective reporting (reporting bias) High risk For visual acuity, trial report states that out-
come was analysed but only reports that re-
sult was not significant
Veterans LAST study
Methods Method of allocation: coded bottles
Masking: participant - yes; provider - yes; outcome - yes
Losses to follow-up: 7 withdrew, 4 lost to follow-up, 3 died. Slightly lower % follow-
up in group 2 (lutein/antioxidant) 80% compared to other 2 groups (lutein alone 86%
placebo 87%)
Participants Country: USA
Number of participants randomised: 90
Approximate average age 75 years
Sex: 86/90 male
Inclusion criteria: atrophic AMD diagnosed by ophthalmoscopy and at least one visual
abnormality: reduced contrast sensitivity, photo-stress glare recovery deficit or deficit on
Amsler grid. Clear ocular media, free of any other ocular/systemic disease that could
affect central or parafoveal macular visual function.
Exclusion criteria: cataract or retinal surgery within 6 months, photosensitising drugs,
taken lutein supplements within the previous 6 months
Interventions Treatment: Group 1 L: lutein 10 mg non-esterified lutein (FloraGlo from Kemin Foods
International, Des Moines, Iowa); Group 2 L/A: lutein plus additional antioxidants and
nutrients (OcuPower (see below) from Nutraceutical Sciences Institute (NSI), Boynton
Beach, Florida); Group 3 P: maltodextrin
Duration: 12 months
Ocupower had a range of nutrients including lutein, vitamin A, beta-carotene, vitamins
C, D3, E, B1, B2, B3, B5, B6, B12, folic acid, biotin, calcium, magnesium, iodine,
zinc copper, manganese, selenium, chromium, molybdenum, lycopene, bilberry extract,
alpha lipoic acid, N-acetyl cysteine, quercetin, rutin, citrus bioflavonoids, plant enzymes,
black pepper extract, malic acid, taurine, L-glycine, L-glutathione, boron
Outcomes The following clinical measurements were made: lens opacity; retinal images; Macular
Pigment Optical Density (MPOD); visual acuity (Snellen) distance and near; glare test-
ing; glare recovery; contrast sensitivity; VFQ-14 (activities of daily living, night driving,
glare recovery symptoms); Amsler grid; self reported vision
Notes It was difficult to extract data on outcomes of relevance to this review: i.e. visual acuity
and progression of AMD
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Veterans LAST study (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “... were randomly assigned to one of three
capsule groups by consecutive random card-3-
choice, allocation sequence” Page 217
Allocation concealment (selection bias) Low risk “Nutraceutical Sciences Institute prepared the
lutein capsules, the L/A capsules, and the P
capsules and also maintained and concealed
the blinding and four-digit allocation codes.
” Page 218
“All personnel at the DVA Medical Center
were unaware of the masked allocation codes
during the 12-month clinical study” Page
218
Blinding of participants and personnel
(performance bias)
Visual acuity
Low risk “All personnel at the DVA Medical Center
were unaware of the masked allocation codes
during the 12-month clinical study” Page
218
“Subjects were provided with opaque capsules
of identical appearance in numbered contain-
ers taken as three capsules twice per day with
food.” Page 218
Blinding of participants and personnel
(performance bias)
Progression AMD
Low risk “All personnel at the DVA Medical Center
were unaware of the masked allocation codes
during the 12-month clinical study” Page
218
“Subjects were provided with opaque capsules
of identical appearance in numbered contain-
ers taken as three capsules twice per day with
food.” Page 218
Blinding of outcome assessment (detection
bias)
Visual acuity
Low risk “All personnel at the DVA Medical Center
were unaware of the masked allocation codes
during the 12-month clinical study” Page
218
“Subjects were provided with opaque capsules
of identical appearance in numbered contain-
ers taken as three capsules twice per day with
food.” Page 218
Blinding of outcome assessment (detection
bias)
Progression AMD
Low risk “All personnel at the DVA Medical Cetnter
were unaware of the masked allocation codes
during the 12-month clinical study” Page
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Veterans LAST study (Continued)
218
“Subjects were provided with opaque capsules
of identical appearance in numbered contain-
ers taken as three capsules twice per day with
food.” Page 218
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss to follow-up 14/90: page 217
Lutein 10 mg group n = 29
• 1 person lost to follow-up
• 1 person died
• 2 other withdrawals
Lutein 10 mg and antioxidant group n =
30
• 2 persons lost to follow-up
• 4 other withdrawals
Placebo group n = 31
• 1 persons lost to follow-up
• 1 person died
• 1 other withdrawals
Members of placebo group removed from
analysis due to the fact that they had taken
lutein
Selective reporting (reporting bias) Unclear risk Difficult to assess with the information
available
Wang 2004
Methods Method of allocation: unknown
Masking: participant - unknown; provider - unknown; outcome - unknown
Losses to follow-up: unknown
Participants Country: China
Number of participants randomised: 400
188 men/212 women aged 52 to 76, average age 65
Interventions Treatment: zinc oxide 80 mg daily, vitamin C, vitamin E
Control: placebo
Duration 24 to 32 months
Outcomes Outcomes: visual acuity, early and late AMD
Notes Limited information available on this trial. AMD patients were stratified into early and
late-stage disease
Risk of bias
Bias Authors’ judgement Support for judgement
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Wang 2004 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Unclear
Blinding of participants and personnel
(performance bias)
Visual acuity
Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
Progression AMD
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
Visual acuity
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
Progression AMD
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear
Selective reporting (reporting bias) Unclear risk Visual acuity was measured but not re-
ported, possibly because of non-significant
results
AMD: age-related macular degeneration
ARM: Age-related maculopathy
ERG: electroretinogram
ETDRS: Early Treatment Diabetic Retinopathy Study
RPE: retinal pigment epithelium
MPOD: macular pigment optical density
NEI: National Eye Institute
VFQ: Visual function questionnaire
RDA: recommended dietary allowance
SD: standard deviation
ZMC: zinc-monocysteine
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bahrami 2006 Not AMD
Barakat 2006 Not antioxidant vitamin
Benzie 2006 Bioavailability study
Bone 2007 Bioavailability study
Cangemi 2007 No control group
Christen 2007 RCT in healthy population group. Included in Cochrane review on prevention of AMD with antioxidant
supplements
Connolly 2011 No AMD outcomes
Cumurcu 2006 Not a RCT
France 1998 Study is probably eligible for inclusion but is unpublished and data are not available
Franciose 2006 Bioavailability study
Goodrow 2006 Bioavailability study
ISRCTN35481392 Participants had no ocular pathology
http://www.controlled-trials.com/ISRCTN35481392/ISRCTN35481392
ISRCTN57556290 No comparator group
http://www.biomedcentral.com/1471-2415/7/3
ISRCTN81595685 Comparison of two active formulations
Kamburoglu 2006 Not a RCT, not antioxidant
Khachik 2006 Bioavailability study
Kopsell 2006 Bioavailability study
Landrum 2012 Pilot study of effects of lutein supplementation on serum and macular pigment
Lim 2006 Not antioxidant
LUNA study Bioavailability study
LUXEA MPOD only measured; no clinical outcomes
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(Continued)
Moeller 2006 Not RCT
NCT00006202 Dose ranging study for lutein supplementation. No control group
NCT00121589 Phase I study only. Looking at changes in plasma levels and macular pigment density only
NCT00563979 Active comparator (omega-3)
NCT00564902 Active comparator (lutein)
NCT00718653 Effect on macular pigments only, not on AMD
Nolan 2006 Not a RCT
Nolan 2007 Not a RCT
Nolan 2012 Effect on macular pigments in healthy people only, not on AMD
Nussenblatt 2006 Not AMD
Owsley 2006 Not antioxidant
PHS II RCT in healthy population group. Will be included in Cochrane Review on prevention of AMD with antiox-
idant supplements
Rosenthal 2006 Small dose ranging study. Data on vision only collected for nine months and not possible to extract from report
Sasamoto 2011 Not a RCT
Vannas 1958 Allocation concealment inadequate
Vidal 2011 RCT inhealthy population group.Will be included inCochrane reviewonpreventionofAMDwith antioxidant
supplements
Wang 2007 Bioavailability study
Wenzel 2006 Bioavailability study
Wong 2010 Phase II open-label study in 10 participants only
Zhao 2006 Bioavailability study
AMD: age-related macular degeneration
MPOD: macular pigment optical density
RCT: randomised controlled trial
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Characteristics of studies awaiting assessment [ordered by study ID]
CARMA
Methods Parallel group randomised controlled trial
Participants Men and women aged 50+ with either early AMD features of sufficient severity in at least one eye or any level of
AMD in one eye and advanced AMD (neovascular AMD or central geographic atrophy) in the fellow eye
n = 433
Interventions Lutein (6mg), zeaxanthin (0.3mg) and co-antioxidants ((vitamin E: 7.5 mg; vitamin C: 75 mg; zinc: 10 mg; copper:
0.2 mg)
Placebo (cellulose microcrystalline, lactose and magnesium stearate) and is indistinguishable from the intervention
preparation in size, colour, smell and taste
Outcomes Primary outcome measure: distance visual acuity
Secondary outcome measures:
• retinal visual acuity
• morphological progression of AMD (grading of stereoscopic colour fundus photographs)
• macular pigment levels and serum levels of antioxidants.
Notes http://www.controlled-trials.com/ISRCTN94557601/CARMA
Dawczynski 2012
Methods
Participants
Interventions
Outcomes
Notes
Falsini 2010
Methods Method of allocation: unclear, report suggests cross-over trial
Masking: participant - unclear; provider - unclear; outcome - unclear although study described as double-masked
Losses to follow-up: unclear
Participants Country: Italy
Number of participants randomised: 25
Age: 54 to 84, mean 65
12 men and 13 women
Interventions Treatment: daily dose of oral saffron (20 mg)
Control: placebo
Duration: 90 days, then crossed over and followed for a further 90 days
56Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Falsini 2010 (Continued)
Outcomes Primary outcome measures:
• fERG amplitude and phase
• fERG function slope and threshold
Secondary outcome measures: visual acuity
Notes http://clinicaltrials.gov/show/NCT00951288
NCT00800995
Methods Allocation: randomised
Control: placebo control
Endpoint classification: efficacy study
Intervention model: parallel assignment
Masking: double-masked (participant, caregiver, investigator, outcomes assessor)
Primary purpose: prevention
Participants n = 46
Interventions Oral administration of Superoxide Dismutase (SOD) in its galenic form, Glisodine, versus placebo
Outcomes Primary outcome measures: difference on AREDS score, month 24 to month 0
Notes http://clinicaltrials.gov/show/NCT00800995
fERG: focal electroretinogram
Characteristics of ongoing studies [ordered by study ID]
AREDS2
Trial name or title Age-Related Eye Disease Study 2 (AREDS2)
Methods Multi-centre parallel group randomised controlled trial, follow-up five years, masked assessment of outcome
Participants 4200 participants aged 50 to 85 years enrolled on the basis of the AREDS Simplified Severity Scale for
defining risk categories for development of advanced age-related macular degeneration
Interventions 10 mg lutein and 2 mg zeaxanthin (1 tablet)
350 mg docosahexaenoic acid (DHA) and 650 mg eicosapentaenoic acid (EPA) (2 soft-gel capsules)
Factorial design, 3 arms (no arm with placebo for both)
Outcomes Primary outcome measures:
• progression to advanced AMD in people at moderate to high risk for progression
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AREDS2 (Continued)
Secondary outcome measures:
• progression to moderate vision loss
• adverse events
• progression of lens opacity or incidence of cataract surgery
• effect of study supplements on cognitive function
• effect of DHA/EPA on cardiovascular morbidity and mortality
Starting date 2006
End date: December 2012
Contact information See clinicaltrials.gov website for details
Notes http://clinicaltrials.gov/show/NCT00345176
NCT00879671
Trial name or title Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-
related macular degeneration
Methods Parallel group randomised controlled trial, masked assessment of outcome
Participants 126 men and women aged 50 to 90 years with non-exudative AMD enrolled on the basis of
AREDS criteria
Interventions Dietary supplement: Lutamax (lutein) 20 mg for 3 months, then lutein 10 mg
Placebo
Outcomes Primary outcome measures:
• macular pigment optical density as measured with optical reflectometry
Secondary outcome measures:
• visual acuity using ETDRS charts
• central visual field defects assessed with scanning laser scotometry
• changes in fundus appearance as documented with fundus photos
• determination of an increased systemic antioxidative state in plasma and low-density lipoprotein and plasma
lutein concentrations
Starting date November 2006
End date: December 2011
Contact information See clinicaltrials.gov website for details
Notes http://clinicaltrials.gov/show/NCT00879671
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NCT00893724
Trial name or title Supplemental Adjuvants for Intracellular Nutrition and Treatment (SAINTS)
Methods Parallel group randomised controlled trial, follow-up one year, masked assessment of outcome
Participants 60 men and women with a clinical diagnosis of neovascular AMD
Interventions Dietary supplement (sustained release)
Dietary supplement with minocycline (50mg)
Placebo
Dietary supplement contains:
• inosine
• tocopherols (200 IU)
• tocotrienol (10 mg)
• coq10 (50 mg)
• niacinamide (750 mg)
• vitamin C (1000 mg)
• n-acetyl cysteine (600 mg)
Outcomes Primary outcome measures:
• degree of regression (optical coherence tomography)
• duration of regression (optical coherence tomography)
• visual change (ETDRS)
Secondary outcome measures:
• effect on HbA1C
• effect on blood pressure
• effect on serum uric acid
Starting date June 2009
End date: September 2011
Contact information See clinicaltrials.gov website for details
Notes http://clinicaltrials.gov/show/NCT00893724
NCT01048476
Trial name or title Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration
Methods Parallel group randomised controlled trial, follow-up one year, masked assessment of outcome
Participants 120 men and women aged 50 to 90 years with nonexudative AMD (AREDS categories 2,3, and 4)
Interventions Dietary supplement: 20 mg lutein; daily supplementation 1 year
Dietary supplement: 10 mg lutein; daily supplementation 1 year
Dietary supplement: placebo; daily supplementation 1 year
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NCT01048476 (Continued)
Outcomes Primary outcome measures:
• macular pigment optical density and visual function, such as visual acuity, multifocal electroretinograms,
contrast sensitivity and glare sensitivity in AMD and healthy participants
Secondary outcome measures:
• serum lutein concentrations and the safety and efficacy of lutein in reducing the risk of the development of
advanced AMD
Starting date September 2009
Contact information See clinicaltrials.gov website for details
Notes http://clinicaltrials.gov/show/NCT01048476
AMD: age-related macular degeneration
DHA: docosahexaenoic acid
EPA: eicosapentaenoic acid
ETDRS: Early Treatment Diabetic Retinopathy Study
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D A T A A N D A N A L Y S E S
Comparison 1. Multivitamin antioxidant vitamin or mineral supplement versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Distance visual acuity: mean 4 161 Std. Mean Difference (IV, Fixed, 95% CI) 0.17 [-0.14, 0.49]
1.1 Mean visual acuity at end
of study
2 79 Std. Mean Difference (IV, Fixed, 95% CI) 0.00 [-0.45, 0.45]
1.2 Change in visual acuity 2 82 Std. Mean Difference (IV, Fixed, 95% CI) 0.34 [-0.10, 0.79]
2 Progression of AMD Other data No numeric data
Comparison 2. Zinc versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Distance visual acuity: loss of 3
or more lines
2 1942 Odds Ratio (Fixed, 95% CI) 0.81 [0.66, 0.99]
2 Distance visual acuity: mean 2 Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Mean visual acuity at end
of study
1 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Change in visual acuity 1 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Progression of AMD:
dichotomous
3 1943 Odds Ratio (Fixed, 95% CI) 0.73 [0.58, 0.93]
Comparison 3. Any multivitamin or single component antioxidant supplement versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Distance visual acuity: loss of 3
or more lines
3 4970 Odds Ratio (Fixed, 95% CI) 0.81 [0.67, 0.98]
2 Distance visual acuity: mean 7 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
2.1 Mean visual acuity at end
of study
4 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Change in visual acuity 3 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Progression AMD: dichotomous 4 Odds Ratio (Random, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Multivitamin antioxidant vitamin or mineral supplement versus placebo,
Outcome 1 Distance visual acuity: mean.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 1 Multivitamin antioxidant vitamin or mineral supplement versus placebo
Outcome: 1 Distance visual acuity: mean
Study or subgroup Antioxidant Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean visual acuity at end of study
AMDSG (1) 35 0.33 (0.41) 24 0.29 (0.24) 37.0 % 0.11 [ -0.41, 0.63 ]
Kaiser 1995 (2) 9 -0.67 (0.2) 11 -0.6 (0.22) 12.7 % -0.32 [ -1.20, 0.57 ]
Subtotal (95% CI) 44 35 49.7 % 0.00 [ -0.45, 0.45 ]
Heterogeneity: Chi2 = 0.67, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
2 Change in visual acuity
Bartlett 2007 (3) 20 0.01 (0.07) 10 -0.02 (0.07) 17.0 % 0.42 [ -0.35, 1.18 ]
Veterans LAST study (4) 25 -0.03 (0.24) 27 -0.14 (0.44) 33.4 % 0.30 [ -0.24, 0.85 ]
Subtotal (95% CI) 45 37 50.3 % 0.34 [ -0.10, 0.79 ]
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
Total (95% CI) 89 72 100.0 % 0.17 [ -0.14, 0.49 ]
Heterogeneity: Chi2 = 1.83, df = 3 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Chi2 = 1.10, df = 1 (P = 0.29), I2 =9%
-2 -1 0 1 2
Favours antioxidant Favours placebo
(1) Right eye: LogMAR score (converted from Snellen decimal acuity) at 18 months
(2) Study eye: Snellen acuity (expressed as decimal) at six months,
(3) Study eye: Change in logMAR score (EDTRS chart) over 9 months
(4) Right eye: Change in logMAR score (converted from Snellen decimal acuity) over 12 months
Analysis 1.2. Comparison 1 Multivitamin antioxidant vitamin or mineral supplement versus placebo,
Outcome 2 Progression of AMD.
Progression of AMD
Study Outcome Antioxidant group Placebo group Comment
AMDSG Right eye:Mean (SD) grade
at end of study (18 months
follow-up)
3.08 (1.22) 3.31 (1.08) ChesapeakeBayWatermanStudy grading sys-
tem (scalewith four categories).Higher grades
reflect more severe disease
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Progression of AMD (Continued)
Bartlett 2007 Study eye: Mean (SD)
change in grade (over 9
months)
0.1 (0.3) 0.3 (0.1) AREDS AMD classification system (scale
with four categories). Higher grades reflect
more severe disease
Analysis 2.1. Comparison 2 Zinc versus placebo, Outcome 1 Distance visual acuity: loss of 3 or more lines.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 2 Zinc versus placebo
Outcome: 1 Distance visual acuity: loss of 3 or more lines
Study or subgroup Zinc Placebo log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
AREDS (1) 897 894 -0.19845 (0.104457) 97.2 % 0.82 [ 0.67, 1.01 ]
Newsome 1988 (2) 80 71 -0.8159 (0.6123) 2.8 % 0.44 [ 0.13, 1.47 ]
Total (95% CI) 977 965 100.0 % 0.81 [ 0.66, 0.99 ]
Heterogeneity: Chi2 = 0.99, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 2.10 (P = 0.036)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours zinc Favours placebo
(1) By person (event in at least one eye): ETDRS chart over an average of 6.3 years
(2) Study eye: ETDRS chart over 24 months
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Analysis 2.2. Comparison 2 Zinc versus placebo, Outcome 2 Distance visual acuity: mean.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 2 Zinc versus placebo
Outcome: 2 Distance visual acuity: mean
Study or subgroup Zinc Placebo
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean visual acuity at end of study
Stur 1996 (1) 37 0.05 (0.12) 41 0.03 (0.14) 0.15 [ -0.29, 0.60 ]
2 Change in visual acuity
Newsome 1988 (2) 40 4.1 (6.2) 37 7.1 (10.95) -0.34 [ -0.79, 0.11 ]
-2 -1 0 1 2
Favours zinc Favours placebo
(1) Study eye: LogMAR score (Bailey-Lovie chart) at 24 months
(2) Study eye: Change in number of correct letters (EDTRS chart) 19 to 24 months
Analysis 2.3. Comparison 2 Zinc versus placebo, Outcome 3 Progression of AMD: dichotomous.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 2 Zinc versus placebo
Outcome: 3 Progression of AMD: dichotomous
Study or subgroup Zinc Placebo log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
AREDS (1) 904 903 -0.3425 (0.1266) 95.8 % 0.71 [ 0.55, 0.91 ]
Holz 1993 (2) 28 30 -0.6931 (1.1533) 1.2 % 0.50 [ 0.05, 4.79 ]
Stur 1996 (3) 37 41 0.8391 (0.7073) 3.1 % 2.31 [ 0.58, 9.26 ]
Total (95% CI) 969 974 100.0 % 0.73 [ 0.58, 0.93 ]
Heterogeneity: Chi2 = 2.82, df = 2 (P = 0.24); I2 =29%
Test for overall effect: Z = 2.50 (P = 0.012)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours zinc Favours placebo
(1) By person (event in at least one eye): progression to advanced AMD over average 6.3 years follow-up
(2) By person: ”new exudative or dry macular lesions” over 12 to 24 months
(3) Study eye: incidence of exudative AMD over 24 months
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Analysis 3.1. Comparison 3 Any multivitamin or single component antioxidant supplement versus placebo,
Outcome 1 Distance visual acuity: loss of 3 or more lines.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 3 Any multivitamin or single component antioxidant supplement versus placebo
Outcome: 1 Distance visual acuity: loss of 3 or more lines
Study or subgroup Antioxidant Placebo log [Odds Ratio] Odds Ratio Weight Odds Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
AREDS (1) 2737 903 -0.2614 (0.1113) 75.4 % 0.77 [ 0.62, 0.96 ]
Newsome 1988 (2) 80 71 -0.8159 (0.6123) 2.5 % 0.44 [ 0.13, 1.47 ]
VECAT (3) 587 592 0.0477 (0.2053) 22.1 % 1.05 [ 0.70, 1.57 ]
Total (95% CI) 3404 1566 100.0 % 0.81 [ 0.67, 0.98 ]
Heterogeneity: Chi2 = 2.77, df = 2 (P = 0.25); I2 =28%
Test for overall effect: Z = 2.14 (P = 0.032)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours antioxidant Favours placebo
(1) By person (event in at least one eye): ETDRS chart over an average of 6.3 years
(2) Study eye: ETDRS chart over 24 months
(3) Worse eye: Loss of 2 or more lines, Bailey-Lovie chart over four years
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Analysis 3.2. Comparison 3 Any multivitamin or single component antioxidant supplement versus placebo,
Outcome 2 Distance visual acuity: mean.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 3 Any multivitamin or single component antioxidant supplement versus placebo
Outcome: 2 Distance visual acuity: mean
Study or subgroup Antioxidant Placebo
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Mean visual acuity at end of study
AMDSG (1) 35 0.33 (0.41) 24 0.29 (0.24) 0.11 [ -0.41, 0.63 ]
Kaiser 1995 (2) 9 -0.67 (0.2) 11 -0.6 (0.22) -0.32 [ -1.20, 0.57 ]
Newsome 2008 (3) 37 -43.43 (4.77) 37 -39.24 (5.6) -0.80 [ -1.27, -0.32 ]
Stur 1996 (4) 37 0.046 (0.12) 41 0.03 (0.14) 0.14 [ -0.30, 0.59 ]
2 Change in visual acuity
Bartlett 2007 (5) 20 0.01 (0.07) 10 -0.02 (0.07) 0.42 [ -0.35, 1.18 ]
Newsome 1988 (6) 40 4.1 (6.2) 37 7.1 (10.95) -0.34 [ -0.79, 0.11 ]
Veterans LAST study (7) 25 -0.03 (0.24) 27 -0.14 (0.44) 0.30 [ -0.24, 0.85 ]
-2 -1 0 1 2
Favours antioxidant Favours placebo
(1) Right eye: LogMAR score (converted from Snellen decimal acuity) at 18 months
(2) Study eye: Snellen acuity (expressed as decimal) at 6 months
(3) Right eye: Number of letters correctly identified (EDTRS chart) at 6 months
(4) Study eye: LogMAR acuity (Bailey Lovie chart) at 24 months
(5) Study eye: Change in logMAR score (EDTRS chart) over 9 months
(6) Study eye: Number of letters lost (EDTRS chart) over 24 months
(7) Right eye: Change in logMAR score (converted from Snellen decimal acuity) over 12 months
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Analysis 3.3. Comparison 3 Any multivitamin or single component antioxidant supplement versus placebo,
Outcome 3 Progression AMD: dichotomous.
Review: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
Comparison: 3 Any multivitamin or single component antioxidant supplement versus placebo
Outcome: 3 Progression AMD: dichotomous
Study or subgroup Antioxidant Placebo log [Odds Ratio] Odds Ratio Odds Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
AREDS (1) 2737 903 -0.3857 (0.1242) 0.68 [ 0.53, 0.87 ]
Holz 1993 (2) 28 30 -0.6931 (1.1533) 0.50 [ 0.05, 4.79 ]
Stur 1996 (3) 37 41 0.8391 (0.7073) 2.31 [ 0.58, 9.26 ]
VECAT (4) 587 592 0.1033 (0.1696) 1.11 [ 0.80, 1.55 ]
0.5 0.7 1 1.5 2
Favours antioxidant Favours placebo
(1) By person (event in at least one eye): progression to advanced AMD over average 6.3 years follow-up
(2) By person: ”new exudative or dry macular lesions” over 12 to 24 months
(3) Study eye: incidence of exudative AMD over 24 months
(4) Worse eye: development of early AMD over four years
A D D I T I O N A L T A B L E S
Table 1. Outcome reporting matrix
√
reported Loss of 3 or more
lines visual acuity
Visual acuity con-
tinuous scale
Progres-
sion of disease: di-
chotomous
Progression
of disease: contin-
uous
Comment
1 AMDSG F F
2 AREDS F F
3 Bartlett 2007 F F
4 CARMIS F C H H
5 Holz 1993 A A H Abstract only
6 Kaiser 1995 F A A
7 LISA F E F
8 Newsome 1998 F
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Table 1. Outcome reporting matrix (Continued)
9 Newsome 2008 F H H
10 Stur 1996 F H
11 VECAT A A H
12 Veterans LAST
study
F F
13 Wang 2004 E E H Limited translation
only
See Appendix 10 for full ORBIT classification.
A: Trial report states that outcome was analysed but only reports that result was not significant (typically stating P > 0.05) (high risk
of bias).
C: Trial report states that outcome was analysed but insufficient data were presented for the trial to be included in meta-analysis or to
be considered to be fully tabulated (low risk of bias).
E: Clear that outcome was measured but not necessarily analysed. Judgement says likely to have been analysed but not reported because
of non-significant results (high risk of bias).
F: Clear that outcome was measured but not necessarily analysed. Judgement says unlikely to have been analysed but not reported
because of non-significant results (low risk of bias).
H: Not mentioned but clinical judgement says unlikely to have been measured at all (low risk of bias).
Table 2. Supplementary information on trials
Study Type of
AMD
Treatment
(dose/day)
Treatment
duration
Follow-up Data on
eyes or peo-
ple?
Visual acu-
ity
Progression
AMD
Notes
AMDSG Early AMD Ocuguard:
Beta-
carotene 20,
000 IU
Vitamin E
200 IU
Vitamin C
750 mg
Citrus
bioflavonoid
complex
125 mg
Quercitin
(bioflavonoid)
50 mg
Bilberry
extract
(bioflavonoid)
18 months 18 months Right and
left eyes re-
ported sepa-
rately
Mea-
sured using
Snellen
chart
but reported
in logMAR:
units
Based on
Chesapeake
Bay grading
but using in-
direct oph-
thal-
moscopy:
expressed
as an average
grade
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Table 2. Supplementary information on trials (Continued)
5 mg
Rutin
(bioflavonoid)
50 mg
Zinc picoli-
nate 12.5
mg
Selenium 50
µg
Taurine 100
mg
N-acetyl
cysteine 100
mg
l-
glutathione
5 mg
Vitamin B2
25 mg
Chromium
100 µg)
AREDS AMD
and VA 20/
32 or better
in 1 eye
956/3640
had AMD
Antioxi-
dants:
Vitamin C
500 mg
Vitamin E
400 IU
Beta-
carotene 15
mg)
Zinc
(zinc oxide
80 mg)
Cupric ox-
ide 2 mg
Factorial de-
sign
Antioxi-
dants x zinc
Average
duration 6.3
years
Average fol-
low-up 6.3
years, 2.4%
lost to fol-
low-up
Person, out-
come “in at
least one
eye”
Loss of 3
ormore lines
VA (equiva-
lent to dou-
bling visual
angle) mea-
sured us-
ing ETDRS
chart
Progression
to advanced
AMD: pho-
tocoagula-
tion or other
treatment
for CNV;
GA involv-
ing centre of
the macula,
RPE detach-
ment, haem-
orrhage un-
der the
retina, sub-
retinal fibro-
sis. Colour
fundus pho-
tography
Bartlett
2007
Soft or
hard drusen,
and areas of
increased
or decreased
pigment
asso-
Lutein esters
6 mg
Retinol 750
mg
Vitamin C
250 mg
Vitamin E
9 months 9 months Trial eye se-
lected
(initial visit
only)
If both
eyes were el-
igible for in-
Change
in logMAR
acuity mea-
sured us-
ing ETDRS
chart
Fundus
photographs
graded using
AREDS
classi-
fication sys-
tem (4 cate-
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Table 2. Supplementary information on trials (Continued)
ciated with
these drusen
34 mg
Zinc 10 mg
Copper 0.5
mg
clusion, the
right eye was
used
gories)
. Mean (SD)
grade was re-
ported
CARMIS AMD in at
least
1 eye having
extensive (as
measured by
drusen area)
interme-
diate (>= 63
mm,
< 125 mm)
drusen;
and at least
one large (>=
125
mm) drusen
or ge-
ographic at-
ro-
phy not in-
volving the
centre of the
macula
Vitamin C
180 mg
Vitamin E
30 mg
Zinc 22.5
mg
Copper 1
mg
Lutein 10
mg
Zeaxanthin
1 mg
Astaxanthin
4 mg
24 months 24 months The eye with
the best VA
was selected.
When both
eyes had the
same
VA, the right
eye was cho-
sen for final
analysis
Letters
and lines re-
ported
as continu-
ous variable
(ETDRS
chart)
Not
reported
Holz 1993 People with
drusen
Zinc sulfate
200 mg
Not stated
but assume
same as fol-
low-up du-
ration
12 to 24 Unclear but
assumed to
be people
Not
reported
“Incidence
of new ex-
udative
or dry mac-
ula lesions”
Kaiser 1995 “Nonserous
AMD”
Visaline:
Buphe-
nineHCL 1.
5 mg
Beta-
carotene 10
mg
To-
copherol ac-
etate 10 mg
Vitamin C
50 mg
6 6 Study eye
identified
Decimal
acuity mea-
sured us-
ing a Snellen
chart
Not
reported
LISA AREDS cat-
egories 2, 3
Lutein
20 mg a day
6 6 Study eye
identified. If
Reported in
graph form,
Not
reported
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Table 2. Supplementary information on trials (Continued)
or 4 for 3months
and then
lutein 10 mg
a day for 3
months
both
eyes were el-
igible,
one eye was
selected ran-
domly
not possi-
ble to extract
data. Mea-
sured us-
ing ETDRS
chart
Newsome
1988
Drusen and/
or pigmen-
tary change,
VA 20/80 or
better
Zinc sulfate
200 mg
12 to 24 12 to 24 Reported by
eye and also
data from 2
eyes
averaged
Number
of letters lost
on EDTRS
chart
Difficult to
extract data
on this. Re-
ported num-
ber with in-
creased pig-
ment,
drusen and
atrophy for
2 observers.
In general
found re-
sults favour-
ing the zinc-
treated
group
Newsome
2008
Pres-
ence of mac-
ular drusen
with or
without pig-
ment
changes
Zinc-mono-
cysteine 25
mg
6 months 6 months Right and
left eyes re-
ported sepa-
rately
Number of
letters read
on EDTRS
chart
Not
reported
Stur 1996 Neovascular
AMD in 1
eye, VA bet-
ter than 20/
40 in other
eye
Zinc sulfate
200 mg
24 24 “Study eye”
which was
fellow eye,
other eye
had neovas-
cular AMD
Mean log-
MAR score
mea-
sured using
Bailey-
Lovie chart
NOTE: pa-
tients with
neovascu-
lar event ex-
cluded from
this
outcome
Incidence
of neovascu-
lar lesion in
study eye
Orig-
inal trial of
n = 500 ter-
minated by
sponsor (As-
tra) because
statis-
tical evalua-
tion of first
40 pa-
tients at 24
months fol-
low-up “did
not show
any treat-
ment bene-
fit”
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Table 2. Supplementary information on trials (Continued)
VECAT Early AMD
(18%) Late
AMD
(0.5%) Rest
presumably
had no signs
of AMD
Vitamin E
500 IU
48 48 “Worse eye” Loss of more
than 9 let-
ters (2 or
more lines)
on (Bailey-
Lovie chart
Investiga-
tors defined
6 stages of
AMD pro-
gression and
defined pro-
gression as
move-
ment from a
lower stage
to a higher
stage in their
worst eye
Veterans
Last study
Atrophic
AMD
and reduced
vision
Lutein 10
mg
Ocupower:
Natural
beta-
carotene
(Betatenem)
15,000 IU
Vita-
min C 1500
mg (as cal-
cium ascor-
bate-Ester
CB)
Vitamin D3
400 IU
Vitamin
E 500 IU (d-
alpha toco-
pherol suc-
cinate) Vita-
min B1 50
mg
Vitamin B2
10 mg
Vitamin B3
70 mg
Vitamin B5
50 mg
Vitamin B6
50 mg
Vitamin
B12 500 µg
Folic acid
12 months 12 months Right and
left eyes re-
ported sepa-
rately
Change
in logMAR
score. Mea-
sured using
Snellen
chart
but reported
in logMAR:
units
Data not re-
ported
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Table 2. Supplementary information on trials (Continued)
800 µg
Biotin 300
µg
Calcium
500 mg
Magnesium
300 mg
Iodine 75 µg
Zinc 25 mg
(as zinc L-
methionine-
L-OptiZ-
incB) Cop-
per 1 mg
Manganese
2 mg
Selenium
200 µg
Chromium
200 µg
Molybde-
num 75 µg
Lycopene
600 µg
Bilberry ex-
tract 160 mg
(stan-
dardised to
25% antho-
cyanosides)
Alpha lipoic
acid 150 mg
N-acetyl
cysteine 200
mg
Quercetin
100 mg
Rutin 100
mg
Citrus
bioflavonoids
250 mg
Plant en-
zymes 50mg
Black pep-
per extract 5
mg (Bioper-
ineB)
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Table 2. Supplementary information on trials (Continued)
Malic acid
325 mg
Taurine 900
mg
L-glycine
100 mg
L-glu-
tathione 10
mg
Boron 2 mg
AMD: age-related macular degeneration
CNV: choroidal neovascularisation
ETDRS: Early Treatment Diabetic Retinopathy Study
GA: geographic atrophy
RPE: retinal pigment epithelium
VA: visual acuity
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Macular Degeneration
#2 MeSH descriptor Retinal Degeneration
#3 MeSH descriptor Retinal Neovascularization
#4 MeSH descriptor Choroidal Neovascularization
#5 MeSH descriptor Macula Lutea
#6 macula* near lutea*
#7 ((macul* OR retina* OR choroid*:TI) AND (degener* OR neovasc*:TI))
#8 ((macul* OR retina* OR choroid*:AB) AND (degener* OR neovasc*:AB))
#9 maculopath*
#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)
#11 MeSH descriptor Vitamins
#12 vitamin*
#13 MeSH descriptor Vitamin A
#14 retinol*
#15 MeSH descriptor beta Carotene
#16 caroten*
#17 MeSH descriptor Ascorbic Acid
#18 ascorbic next acid
#19 MeSH descriptor Vitamin E
#20 MeSH descriptor alpha-Tocopherol
#21 alpha tocopherol*
#22 MeSH descriptor Vitamin B 12
#23 cobalamin*
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#24 MeSH descriptor Antioxidants
#25 antioxidant* or anti oxidant*
#26 MeSH descriptor Carotenoids
#27 carotenoid*
#28 MeSH descriptor Zinc
#29 zinc*
#30 MeSH descriptor Riboflavin
#31 riboflavin*
#32 MeSH descriptor Selenium
#33 selenium*
#34 MeSH descriptor Lutein
#35 lutein*
#36 MeSH descriptor Xanthophylls
#37 xanthophyll*
#38 zeaxanthin*
#39 (#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24)
#40 (#25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38)
#41 (#39 OR #40)
#42 (#10 AND #41)
Appendix 2. MEDLINE (OvidSP) search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp macular degeneration/
14. exp retinal degeneration/
15. exp retinal neovascularization/
16. exp choroidal neovascularization/
17. exp macula lutea/
18. (macula$ adj2 lutea).tw.
19. ((macul$ or retina$ or choroid$) adj4 degener$).tw.
20. ((macul$ or retina$ or choroid$) adj4 neovasc$).tw.
21. (AMD or ARMD or CNV).tw.
22. maculopath$.tw.
23. or/13-22
24. exp vitamins/
25. exp vitamin A/
26. vitamin A.tw.
27. retinol$.tw.
28. exp beta carotene/
29. (caroten$ or betacaroten$).tw.
30. exp ascorbic acid/
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31. ascorbic acid$.tw.
32. vitamin C.tw.
33. exp Vitamin E/
34. exp alpha tocopherol/
35. alpha?tocopherol$.tw.
36. alpha tocopherol$.tw.
37. vitamin E.tw.
38. exp Vitamin B12/
39. vitamin B12.tw.
40. cobalamin$.tw.
41. exp antioxidants/
42. ((antioxidant$ or anti) adj1 oxidant$).tw.
43. exp carotenoids/
44. carotenoid$.tw.
45. exp zinc/
46. zinc$.tw.
47. exp riboflavin/
48. riboflavin$.tw.
49. exp selenium/
50. selenium$.tw.
51. exp lutein/
52. lutein$.tw.
53. exp xanthophylls/
54. xanthophyll.tw.
55. zeaxanthin$.tw.
56. or/24-55
57. 23 and 56
58. 12 and 57
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (Glanville 2006).
Appendix 3. EMBASE (OvidSP) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
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21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp retina macula degeneration/
34. exp retina degeneration/
35. exp retina neovascularization/
36. exp subretinal neovascularization/
37. (AMD or ARMD or CNV).tw.
38. ((macul$ or retina$ or choroid$) adj4 degener$).tw.
39. ((macul$ or retina$ or choroid$) adj4 neovasc$).tw.
40. exp retina macula lutea/
41. (macula$ adj2 lutea$).tw.
42. maculopath$.tw.
43. or/33-42
44. exp vitamins/
45. exp Retinol/
46. vitamin A.tw.
47. retinol$.tw.
48. exp beta carotene/
49. (caroten$ or betacaroten$).tw.
50. exp ascorbic acid/
51. ascorbic acid$.tw.
52. vitamin C.tw.
53. exp alpha tocopherol/
54. alpha?tocopherol$.tw.
55. alpha tocopherol$.tw.
56. vitamin E.tw.
57. vitamin B12.tw.
58. exp cyanocobalamin/
59. cobalamin$.tw.
60. exp antioxidants/
61. ((antioxidant$ or anti) adj1 oxidant$).tw.
62. exp carotenoid/
63. exp zinc/
64. zinc$.tw.
65. exp riboflavin/
66. riboflavin$.tw.
67. exp selenium/
68. selenium$.tw.
69. exp zeaxanthin/
70. zeaxanthin$.tw.
71. lutein$.tw.
72. xanthophyll.tw.
73. or/44-72
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74. 43 and 73
75. 32 and 74
Appendix 4. AMED (OvidSP) search strategy
1. exp eye disease/
2. exp vision disorders/
3. exp retinal disease/
4. maculopath$.tw.
5. ((macul$ or retina$ or choroid$) adj3 degenerat$).tw.
6. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
7. or/1-6
8. exp vitamins/
9. vitamin A.tw.
10. retinol$.tw.
11. exp carotenoids/
12. caroten$.tw.
13. exp ascorbic acid/
14. ascorbic acid$.tw.
15. vitamin C.tw.
16. vitamin E.tw.
17. alpha tocopherol$.tw.
18. vitamin B12.tw.
19. cobalamin$.tw.
20. exp antioxidants/
21. ((antioxidant$ or anti) adj1 oxidant$).tw.
22. zinc/
23. zinc$.tw.
24. riboflavin$.tw.
25. selenium/
26. selenium$.tw.
27. lutein$.tw.
28. xanthophylls.tw.
29. zeaxanthin$.tw.
30. or/8-29
31. 7 and 30
Appendix 5. OpenGrey search strategy
macular degeneration AND antioxidant
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Appendix 6. metaRegister of Controlled Trials search strategy
(macular degeneration) AND (antioxidant or vitamin or carotene or selenium or tocopherol)
Appendix 7. ClinicalTrials.gov search strategy
(Macular Degeneration) AND (Antioxidant OR Vitamin OR Carotene OR Selenium OR Tocopherol)
Appendix 8. ICTRP search strategy
Macular Degeneration = Condition AND Antioxidant OR Vitamin OR Carotene OR Selenium OR Tocopherol = Intervention
Appendix 9. MEDLINE (OvidSP) adverse effects search strategy
1. exp retinal degeneration/
2. retinal neovascularization/
3. choroidal neovascularization/
4. exp macula lutea/
5. (macula$ adj2 lutea).tw.
6. ((macul$ or retina$ or choroid$) adj4 degener$).tw.
7. ((macul$ or retina$ or choroid$) adj4 neovasc$).tw.
8. (AMD or ARMD or CNV).tw.
9. maculopath$.tw.
10. or/1-9
11. exp vitamins/
12. vitamin A.tw.
13. retinol$.tw.
14. (caroten$ or betacaroten$).tw.
15. ascorbic acid$.tw.
16. vitamin C.tw.
17. alpha?tocopherol$.tw.
18. alpha tocopherol$.tw.
19. vitamin E.tw.
20. ((antioxidant$ or anti) adj1 oxidant$).tw.
21. zinc/
22. zinc$.tw.
23. or/11-22
24. 10 and 23
25. ae.fs.
26. 24 and 25
27. limit 26 to (meta analysis or randomized controlled trial or “review”)
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Appendix 10. ORBIT classification
The Outcome Reporting Bias In Trials (ORBIT) study classification system for missing or incomplete outcome reporting in
reports of randomised trials
Description Level of reporting Risk of bias*
Clear that the outcome was measured and analysed
A Trial report states that outcome was
analysed but only reports that result
was not significant (typically stating P
> 0.05)
Partial High risk
B Trial report states that outcome was
analysed but only reports that result
was significant (typically stating P <
0.05)
Partial No risk
C Trial report states that outcome was
analysed but insufficient data were
presented for the trial to be included
in meta-analysis or to be considered
to be fully tabulated
Partial Low risk
D Trial report states that outcome was
analysed but no results reported
None High risk
Clear that the outcome was measured
E Clear that outcome was measured but
not necessarily analysed. Judgement
says likely to have been analysed but
not reported because of non-signifi-
cant results
None High risk
F Clear that outcome was measured but
not necessarily analysed. Judgement
says unlikely to have been analysed
but not reported because of non-sig-
nificant results
None Low risk
Unclear whether the outcome was measured
G Not mentioned but clinical judge-
ment says likely to have been mea-
sured and analysed but not reported
on the basis of non-significant results
None High risk
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(Continued)
H Not mentioned but clinical judge-
ment says unlikely to have been mea-
sured at all
None Low risk
Clear that the outcome was not measured
I Clear that outcome was not measured NA No risk
Appendix 11. Results of searches for previous versions of this review
The original electronic searches identified 577 reports of possible AMD trials of which five reports (four trials) were of antioxidant
interventions (AMDSG; Kaiser 1995; Newsome 1988; Stur 1996). These four trials met the inclusion criteria for this review. Contact
with a trial author identified an additional trial of zinc supplementation that has been published in abstract form only (Holz 1993).
In October 2001, the result of the Age-Related Eye Disease Study (AREDS) was published. The reference list of this study report
identified that the Vitamin E, Cataract and Age-related Maculopathy Study (VECAT) had been published in abstract form.
Searching the reference lists of trial reports located one further possible relevant trial (Vannas 1958). This study was not included in
the review because there was no evidence from the report that the comparison groups (heparin, vitamin A and E, Hydergin therapy
and placebo) were randomly allocated or that the allocation was concealed in any way. As the trial was conducted in 1958, we made
no further attempt to clarify this.
A trial of zinc supplementation (30 mg daily) of people with neovascular AMD in one eye and drusen in the other (n = 170) has been
conducted and is as yet unpublished (France 1998a). This trial is listed as ’Awaiting assessment’ in this review.
Searches were first performed in August 1997 and repeated in October 1998, December 1999, September 2000, November 2001 and
May 2005. Two further trials were identified: Veterans LAST study and Wang 2004 and have been incorporated into the review. The
searches were updated in January 2006 and August 2007 but no new trials were identified.
WH A T ’ S N E W
Last assessed as up-to-date: 20 August 2012.
Date Event Description
11 July 2012 New search has been performed Issue 9, 2012: John Lawrenson assisted with this review
update
11 July 2012 New citation required but conclusions have not changed Issue 9, 2012: Update searches were conducted and 3 new
trials have been added to the review
81Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
H I S T O R Y
Protocol first published: Issue 3, 1997
Review first published: Issue 1, 1998
Date Event Description
28 August 2008 Amended Converted to new review format.
12 August 2007 New search has been performed Issue 1 2008: Results of trial from China (Wang et al)
added. Report from AREDS study on risk of hospital
admission due to genitourinary complications in people
taking high-dose zinc.
Graphs with only one trial have been deleted and results
have been reported in the text
19 January 2006 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
JE wrote the protocol and completed the first published version of this review.
JGL checked all the data in the originally published review.
For this update (2012) both authors searched for new studies, did ’Risk of bias’ assessment and extracted data. JE cut and pasted data
into RevMan and updated the text. JGL checked the data and provided comments on the text.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Moorfields Eye Hospital NHS Trust, UK.
82Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
External sources
• Guide Dogs for the Blind Association, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The original protocol was published in 1996. Since then there have been several improvements in review methods including:
• Risk of bias assessment;
• Summary of findings table.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antioxidants [∗therapeutic use]; Dietary Supplements; Macular Degeneration [∗prevention & control]; Minerals [∗therapeutic use];
Randomized Controlled Trials as Topic; Vitamins [∗therapeutic use]
MeSH check words
Aged; Humans
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